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ABSTRACT 
 
A. During our attempts to synthesize substituted enediynes, coupling reactions between 
terminal alkynes and 1,2-cis-dihaloalkenes under the Sonogashira reaction conditions 
failed to give the corresponding substituted enediynes. Under these conditions, terminal 
alkynes underwent self-trimerization or tetramerization. In an alternative approach to 
access substituted enediynes, treatment of alkynes with trisubstituted (Z)-
bromoalkenyl-pinacolboronates under Sonogashira coupling conditions was found to 
give 1,2,4,6-tetrasubstituted benzenes instead of Sonogashira coupled product. The 
reaction conditions and substrate scopes for these two new reactions were investigated. 
 
B. BODIPY core was functionalized with various functional groups such as 
nitromethyl, nitro, hydroxymethyl, carboxaldehyde by treating 4,4-difluoro-1,3,5,7,8-
pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene with copper (II) nitrate 
trihydrate under different conditions. Further, BODIPY derivatives with alkyne and 
azido functional groups were synthesized and conjugated to various glycosides by the 
Click reaction under the microwave conditions. One of the BODIPY–glycan conjugate 
was found to form liposome upon rehydration. The photochemical properties of 
BODIPY in these liposomes were characterized by fluorescent confocal microscopy. 
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Enediynes as an effective DNA-
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1.1 Enediyne-containing natural products 
In the late 1980s, the discovery of new enediyne natural products generated enormous 
research interest in the scientific community in both academia and industry. These 
compounds were isolated from bacteria and proved to have powerful antibiotic and 
anti-cancer properties.1,2,3 Afterwards, researchers from various disciplines have shown 
increased attention to its chemistry, biology and potential medicinal applications. So 
far nearly 40 enediyne-containing compounds have been isolated from various natural 
sources, with a few of them exhibiting activities a few orders of magnitude higher than 
the existing antitumor and antibiotics. For example, calicheamicin-γ1 and shishijimicin 
A are nearly 4,000 and 13,000 times, respectively, more potent than the widely known 
antitumor agent adriamycin. The commonly known potent antitumor and antimicrobial 
enediynes (Figure 1-1) include calicheamicin, 4  esperamicin,1 dynemicin, 5 
neocarzinostatin, 6  kedarcidin, 7  namenamicin, 8  maduropeptin, 9  N1999A2 10  and 
shishijimicin,11 and the recently found uncialamycin.12 Among these natural enediynes, 
calicheamicin and neocarzinostatin are well studied and approved for clinical uses. The 
other enediyne natural products also proved to have anticancer properties in in vitro 
studies.  
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Figure 1-1: Natural enediyne compounds 
 
 These enediyne antibiotics and antitumour compounds attracted interest from 
researchers not only for their structural complexity, but also their remarkable biological 
activities.  These compounds, however, do not exhibit cell specificity, which typically 
lead to severe toxicity as therapeutic agents. To address the specificity problem, 
polymer-based and antibody-conjugated derivatives of enediyne natural products have 
been developed.13 ,14 ,15  For example, calicheamicin-antibody (IgG4) conjugate was 
approved in the US in 2000 for treating acute myloid leukemia (AML),14 and marketed 
under the trade-name Mylotarg®. The antibody portion of Mylotarg binds specifically 
to the CD33 antigen, a sialic acid-dependent adhesion protein found on the surface of 
leukemic blasts and immature normal cells of myelomonocytic lineage, but not on 
normal hematopoietic stem cells.16  A poly(styrene-co-maleic acid)-neocarzinostatin 
conjugate was also approved in 1993 in Japan and marketed to treat hepatoma.17 These 
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examples demonstrated the potential to improve target specificity of enediynes through 
appropriate drug delivery systems.  
 
1.2 Mechanism of action of enediynes  
Enediyne-containing natural products are very diverse in structure, but they also share 
some common structural and functional features. Three distinct structural motifs are 
commonly found in these compounds. One part of the structure is responsible for 
binding to the target such as DNA, while the second part acts as a molecular trigger to 
activate the molecule at the target site. These two regions are quite different in the 
chemical composition among enediyne natural products. The third part of the molecule 
is enediyne, which is responsible for their potent biological activity through a reaction 
called Bergman cyclization as shown in Figure 1-2. Bergman cyclization was first 
reported in 1972,18 where Z-enediynes were activated by heating to cyclize to form a 
biradical intermediate, which then abstracts hydrogen atoms from a donor to generate 
a benzene ring.  
 
Figure 1-2: Bergman cyclization 
The mode of action of natural enediyne molecules is explained below using 
calicheamicin as an example. Calicheamicin consists of three distinct structural regions 
(Figure 1-3). The larger of three, coloured in green, consists of four monosaccharide 
units joined by unusual linkages such as a thioester and a hydroxylamine glycosidic 
linkage.  
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Figure 1-3: Structure of calicheamicin 
The oligosaccharide motif, highlighted in green, presumably binds to the minor groove 
of DNA duplex in a sequence specific manner.19,20 It was found that the carbohydrate 
tail in calicheamicin determines the sequence specificity for cytosine- containing 
oligopyrimidine tracts such as TCCT, TCCC, TCCA, ACCT, TCCG, GCCT, CTCT, 
and TCTC.21 After docking the drug into the minor groove of the DNA, activation of 
calicheamicin occurs by the reaction of the triggering moiety and an external substance. 
In calicheamicin a trisulfide functionality acts as a triggering device. Thus, an attack by 
nucleophiles, such as glutathione, on the trisulfide activates the enediyne functionality 
in the molecule by a series of steps (Figure 1-4).22  
 
Figure 1-4: The activation and DNA cleavage mechanism of Calicheamicin.22 
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In this activation process an external nucleophile attacks the central sulfur atom of 
trisulfide, leading to the formation of nucleophilic thiolate or thiol, which subsequently 
undergoes a Micheal addition on the unsaturated carbonyl group. As a result of this 
reaction, the β -carbon of the unsaturated carbonyl is converted from sp2 to sp3 
hybridization, giving rise to strain in the 10-membered ring that contains the enediyne 
functionality. This strain is relieved by bringing the two alkyne moieties closer, which 
then lowers the activation energy of the enediyne for the Bergman cyclization.  Upon 
cyclization, a highly reactive species 1,4-benzenoid biradical is formed.18 The newly 
formed benzenoid radicals are positioned in the DNA such that they can abstract two 
hydrogen atoms from the sugar (either at C4’, C5’ or C1’) backbone of DNA, which 
ultimately leads to strand breakages (Figure 1-5).23, 24, 25, 26 
 
 
Figure 1-5: DNA cleavages by abstracting the 5’-H of sugar backbone 
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1.3 Synthetically prepared enediynes and their biological activities 
 
Due to the limited availability of enediyne compounds from natural sources, chemical 
synthesis of enediynes has been pursued by a number of academic laboratories. To date, 
only a few successful total syntheses of naturally occurring enediynes have been 
reported, however, synthesis of a number of model systems have been accomplished 
that led to better understanding of the enediyne chemistry. As discussed previously, the 
active functional group in naturally occurring enediyne is Z-enediyne. As shown in a 
1972 publication by Bergmann et al.,18 Z-enediyne reacts to give benzene-related 
products upon heating. It was found that a highly reactive benzenoid radical species 
was formed during the reaction, which, upon abstraction of hydrogen atoms from a 
hydrogen atom source, led to the formation of benzene derivatives. Although this 
reaction is useful for making substituted benzene derivatives, it did not attract much 
interest in the synthetic chemist community due to the availability of several other 
methods for making substituted benzenes. Interest in the Bergman cyclization was 
revived, however, after the discovery of enediyne natural products where the heart of 
their activity mainly depends on the enediyne cyclization. The combination of 
experimental and computational investigations revealed the factors that affect the 
reactivity of enediynes.27 In this respect, higher activities of enediynes are always 
attained when 1) the distance between two terminal acetylene carbons is shorter, 2) a 
higher order of strain is present in the enediyne, or 3) a higher concentration of trapping 
solvent, i.e. source of hydrogen atoms, is present. Several enediynes were synthesized 
for the better understanding of the mechanism of action of naturally occurring 
enediynes, and to find the substitution effects and metal complexation on the cylization 
temperatures. Enediynes that can be activated by various triggers were also synthesized.  
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K. C. Nicolaou et al. synthesized the first generation of enediynes 1, which have 
a simple cyclic structure (Figure 1-6). 28  A compound with 10-membered cyclic 
structures (n = 2) has the ability to undergo Bergman cyclization at room temperature 
while the larger rings required higher temperatures. The same research group also 
prepared water soluble cyclic enediyne 2, which could undergo cyclization at 37°C.28 
 
Figure 1-6: First generation of synthetic enediynes 
 
These compounds were found to cleave DNA in in vitro experiments. Maier et 
al. synthesized bicycle derivative 3, which is stable at room temperature but undergoes 
Bergman cyclization at elevated temperatures (80°C).29 The stereochemistry of the 
isolated compound 3 was not assigned. The molybdenum complex of enediyne 
compound 4 prepared by Bhattacharyya et al. was found to undergo Bergman 
cyclization more readily than the free enediyne. 30  Work on these first generation 
enediynes motivated further design and synthesis of new enediynes. There are two 
broad classes of chemically synthesized enediynes: cyclic and acyclic. In addition, 
thermal or photo-triggers were also incorporated into these enediynes. Research on 
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these synthetic enediynes will be discussed here. Some of these enediynes have been 
evaluated for their anticancer properties as well.   
To identify the role of steric bulk at the terminal carbons of the acetylene bonds 
in enediyne in the cyclization, a series of enediyne compounds were synthesized and 
their cyclization temperatures were analyzed through differential scanning calorimetry 
(DSC). When the enediyne undergoes cyclization, the radical intermediate undergoes 
polymerization in the absence of a source of hydrogen atoms that can be readily 
abstracted. The polymerization reaction is exothermic, thus DSC can be used to monitor 
heat produced from Bergman cyclization at a range of temperatures.31 A peak in DSC 
at a provided temperature is considered to be the starting point of cyclization or 
temperature required for the cyclization. A series of enediynes with amino functionality 
(Figure 1-7) at both termini of alkynes were prepared to examine the effect of steric 
bulk on the cyclization temperature.32 
 
  
 
Figure 1-7: Enediynes with substituted amine and the corresponding cyclization 
temperature 
 
Based on the DSC measurement, enediyne with dimethyl amine at both termini 
of alkynes (Compound 5) requires the highest cyclization temperature, but when the 
number of methyl substitutions decreases (Compounds 6 and 7), cyclization 
temperature decreases.32 There is a nearly 80°C difference in the temperature required 
for Bergman cyclization between the fully methylated 5 and non-methylated enediyne 
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7. Another enediyne 8 with an aromatic ring was also shown to require higher 
temperature for cyclization to occur.32 This study provided insights of the steric effect 
on Bergman cyclization. The lower onset temperature requirement of the free amine-
containing enediyne was thought to be useful for designing therapeutically important 
metal enediyne complexes.   
Enediynes-containing aromatic and hetero aromatic groups were synthesized 
and their biological activities were evaluated against selected cancer cell lines. Lin et 
al. reported thermally stable enediynes with aromatic substitutions at both termini of 
the two alkynyl groups (Figure 1-8).33  
 
 
Figure 1-8: Enediynes with aromatic and hetero aromatic substitutions 
 
 
 
11 
 
In the cell cycle analysis, all these compounds (9-13) showed moderate to high 
apoptotic induction. Compounds 9 and 10 were shown to inhibit growth on 60 cancer 
cell lines with average IC50 values ranging from 0.01 to 96.9 mM.
34,35 Another enediyne 
13, THDA (2-(6-(2-thieanisyl)-3(Z)-hexen-1,5-diynyl)aniline), was found to be active 
against human leukemia K562 cells.  Enediynes with a terminal OH group have been 
prepared and shown to have good cytotoxic activity against cancer cells (Figure 1-9).36 
Among this group of enediynes, the compound with 4-trifluoromethyl phenyl was 
shown as the most potent growth inhibitor against tumor cell lines at low 
concentrations, and blocked the cell cycle at G2/M phase via controlling cyclin A and 
Cdc25C expression.36  
 
 
Figure 1-9: Enediynes with a hydroxyl side chain 
 
Inspired by the robust anticancer agent cisplatin, a few metal complexes of enediynes 
have been prepared. One active research area in the enediynes focuses on the use of 
metal ions to promote the Bergmann cyclization. The enediynes designed for metal 
complexation should have a chelating functionality. In most cases, metal ion 
complexation lowers the Bergmann cyclization temperature, however, enediyne – 
metal complexes with higher cyclization temperatures were also observed (Scheme 1-
1).  The enediyne with phosphine groups (14) undergoes Bergman-cyclization at 243°C 
but the complexes formed with Pd2+ and Pt2+ ions (15) showed a dramatic decrease in 
the cyclization temperature to give clyclized product 16.37 In the case of complex 
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formed with Hg2+ there was no observed cyclization, even at 450°C.37 These 
experiments clearly suggest that electronic factors have an important role in the 
cyclization of enediynes.  
 
Scheme 1-1: enediynes with phosphine ligands 
 
Bipyridyl-based macrocyclic enediyne (Scheme 1-2) was synthesized and their 
cyclization temperatures determined.38 ,39  Although it was proposed that the cyclic 
network can reduce the cyclization temperature, the conformation of the cyclic structure 
is also important. In bipyridyl-based enediynes, two pyridyl moieties are in the transoid 
form (17) due to steric repulsions, but are converted to the cisoid conformation (18) 
upon metal ion complexation, and undergo cyclization at lower temperatures. 
13 
 
 
Scheme 1-2: Enendiynes with bypiridyl ligands 
 
In addition to metal-ion complexation, another widely explored strategy to activate 
enediynes towards Bergman cyclization is photo irradiation. 40  In this strategy, an 
enediyne locked from cyclization is activated through exposure to a light source. For 
example, in compound 19 (Scheme 1-3), the amino group is masked with a photo labile 
protecting group. Upon exposure to light at 365 nm, the protecting group is removed to 
generate a free amine, which then reacts with the ketone to form an imine and a cyclic 
enediyne (20).41 The cyclic enediyne, in turn, undergoes Bergman cyclization to form 
a biradical compound (21) that cleaves plasmid DNA at ambient temperatures.  
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Scheme 1-3: DNA cleavages by photo enediyne activated by deprotection of a 
photolabile amino protecting group 
 
Popik et al. reported an enediyne in which one of the acetylene bonds was masked by 
a cyclopropenone (22) (Scheme 1-4).42 Irradiation of this compound led to unmasking 
of the acetylene bond through the release of carbon monoxide, consequently generating 
an enediyne which spontaneously underwent Bergman cyclization to produce aromatic 
radicals (23). These aromatic radicals abstracted hydrogen atoms from hydrogen 
donors, such as 1,4-cyclohexadiene (1,4-CHD), to give compound 24. 
 
Scheme 1-4: DNA cleavage by enediyne activated photochemically 
 
Nicolaou et al. synthesized model analogs of a naturally occurring enediyne, dynemicin 
(Figure 1-10, 25-28), in order to understand the essential features of this natural 
product for the activation of cycloaromatization.43 One of the proposed pathways for 
the activation of dynemicin suggests that donation of the lone pair electrons from the 
nitrogen atom leads to the opening of the epoxide ring, introducing a great deal of strain 
in the molecule that is then rapidly relieved by cycloaromatization of enediyne core. 
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This proposed pathway was verified through studies of dynemycin analogues, asserting 
that the electron density on the nitrogen atom indeed participates in the activation of 
dynemicin through the opening of the epoxide ring.  
 
Figure 1-10: Analogues of dynemycin 
 
The synthesized model compounds 26 and 27, which are very labile, underwent 
cycloaromatization very rapidly at ambient temperatures due to the electron-pushing 
ability of nitrogen in 26 and oxygen in 27. While compound 25 was stable under 
thermal conditions, it was activated under acidic conditions, as the opening of epoxide 
occurs under acidic conditions. The understanding of the importance of the electron 
density on the nitrogen in activating the enediyne core for the aromatic cyclization led 
to the design of a 2-(phenylsulfonyl)ethyl carbamate 28.44  The nitrogen-protecting 
group in compound 28 was shown to be easily removed under mild basic conditions 
and to undergo slow deprotection at physiological pH. Further, the same authors 
showed that compound 26 that contain a free amine can be used as a prodrug.  
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Compound 28 has an IC50 of 2.010-14 M against the MOLT-4 leukemia cell line, 
demonstrating it to be a potent in vitro antitumor agent.44 
 
Another interesting enediyne compound conjugated with the pyrrolo[2,1-c] 
[1,4]benzodiazepine (PBDs) was prepared.45 PBDs are a class of naturally occurring 
compounds, such as anthramycin, DC-81, tomaymycin and sibiromycin, isolated from 
various Streptomyces species and proved to have potent antitumor activity.52 PBDs are 
DNA minor groove binders. Mechanistic studies revealed that PBDs form irreversible 
covalent bond with DNA through alkylation of N-2 of guanine nucleotide as shown in 
Figure 1-11. This reaction leads to DNA lesions and inhibit gene function.  
 
 
Figure 1-11: Covalent bond formation between DNA and a PBD 
 
This ability of PBDs to bond to DNA became attractive to medicinal chemists in 
designing molecules that target DNA. Since enediyne molecules are known to target 
and cleave DNA, attachment of a DNA binding molecule to the enediyne may improve 
the target specificity. On this basis, a few enediynes–PDB conjugates were synthesized 
(Figure 1-12: 29 and 30) and proved to have higher cytotoxicity than PDB against 
human cancer cell lines.45   
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Figure 1-12: PBDs conjugated enediynes 
 
Another interesting note is that enediynes have been incorporated into the biologically 
active molecule Combretastatin A-4 (CA-4) 31. 46 The structurally simple CA-4 was 
found to be cytotoxic against cancer cells.47,48,49 The toxicity of this molecule was 
attained by inhibiting the tubulin polymerization. One of its water-soluble phosphate 
derivatives (CA-4P) 31 entered Phase-II clinical trial in 2005. Several chemical 
modifications have been introduced to the natural Combretastatin to modulate its 
activity. Provot et al. was inspired by the biological action of Combretastatin and 
synthesized Combretastatin derivatives containing enyne and enediyne in order to 
understand the structure–activity relationship on inhibiting the tubulin polymerization 
(Figure 1-13: 32 and 33).56 The tubulin polymerization was inhibited only by two of 
these derivatives with IC50 values ranging from 60–70 µM which is much lower than 
the activity of Combretastatin, while other compounds did not exhibit any activity. The 
results of this study revealed that incorporation of enyne and endiyne into 
combretastatin does not have any effect on improving its anticancer activity.46 
18 
 
 
Figure 1-13: Enediynes with similar structure of Combretastatin 
 
1.4 Potential of enediyne as site-specific DNA cutters 
Although the DNA-cleaving ability of the enediyne functionality has been explored for 
its anticancer and antimicrobial proprieties, there is a potential to develop this 
functionality as DNA cutters or site-specific DNA cleaving agents, which can be very 
useful in DNA manipulation. Currently, DNA manipulation employs the use of 
restriction enzymes and ligases. 50  This method cannot be applied to site-specific 
manipulation of genomes, as restriction enzymes recognise 4-8 base pair sequences, 
site-specific cleavages of large DNAs, such as genomes, by these enzymes cannot be 
achieved as these cleavages typically lead to the formation of a large number of 
fragments. Thus, there is a need for a tool that can cleavage large DNAs in a site-
specific fashion. Several chemistry-based artificial DNA cutters have been reported in 
the literature.51  In these DNA cutters, a DNA-cutting molecule is combined with the 
sequence-recognising molecule such as the oligonucleotide sequence. Since the 
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scission site in the target DNA strand is recognised by the DNA cutters through 
Watson-Crick base pairs, site-specific cleavage within a given region in a long DNA 
sequence can be accomplished. DNA cutters cleave target DNA, single stranded or 
double stranded, either by oxidative or hydrolytic cleavage of the phosphodiester 
backbone. Chu and Orgel covalently attached EDTA to a 16-mer deoxyoligonucleotide 
sequence at the 5’-terminus through an ethylene diamine linker (Figure 1-14).52 This 
sequence acted as a hybridization-dependent DNA cutter, cleaving a 37-mer single 
stranded target DNA in the presence of Fe2+, dithiothreitol, and oxygen. The Fe2+ 
complex of EDTA acts as a radical initiator responsible for the oxidative cleavage of 
target DNA. The cleavage site in the target 37-mer strand has approximately four 
residues on each side of the terminal phosphate of the 16-mer DNA cutter.  
 
Figure 1-14: EDTA conjugated oligo nucleotide 
 
Dervan et al. reported a single stranded DNA-cutter in which a 19-mer 
deoxyolionucleotide containing a metal chelator EDTA covalently attached to the 
thymidine residue at the 10th position of the 19-mer (Figure 1-15).53 This 19-mer DNA 
cutter was able to specifically cleave the 167-nt target site in the presence of Fe2+, 
dithiothreitol, and oxygen. The cleavage site in the target strand is within a range of 16-
nt at the site of hybridization.  
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Figure 1-15: EDTA containing thymidine 
 
Unlike single-stranded DNA-cutters, double-stranded DNA-cutters need to be 
constructed with specific types of recognition elements such as triple-helix-forming 
oligonucleotides, and minor groove binders that recognize the double strand.54,55 For 
example, the oligonucleotide of a homopyrimidine sequence can be used as a 
recognition element in cutters for double stranded DNA. This sequence recognizes the 
homopurine/homopyrimidine sequence in the target double-stranded DNA by forming 
a triple helix structure. Recognition element homopyrimidine sequence attached to 
either the Fe2+/EDTA complex56 or Cu2+/phenanthroline complex57 have been reported 
to perform site-specific cleavage of double stranded DNA through oxidative reaction.  
 
1.5 General perspectives and objectives of this project 
1.5.1 Synthesis and conjugation of enediyne functionality to oligo- 
nucleotides  
 
As discussed above, the enediyne functionality is known to be the pharmacophore in a 
number of natural products that exhibit anti-cancer and antimicrobial properties. Our 
objectives for this project are to attach the enediyne functionality to an oligonucleotide 
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and investigate its ability to cleave DNA in a site-specific fashion. As an enediyne 
activating functionality, a Schiff base will be introduced in the designed enediyne, 
which activates the enediyne for cyclization upon binding to metal cations. It was 
already reported that an enediyne with Schiff base attached at the terminal carbons of 
acetylene bonds would undergo Bergman cyclization at room temperature in the 
presence of magnesium chloride (Scheme 1-5).58 Enendiyne 34 containing Schiff bases 
first form a complex 35 with magnesium ions, lowering the activation energy for the 
cyclization. This enediyne-magnesium complex then undergoes Bergman cyclization 
at room temperature, and in the presence of a hydrogen donor, gives aromatized product 
36.  
 
 
Scheme 1-5: Enendiyne cyclization at room temperature in the presence of Mg2+ ions 
 
A synthetic scheme was designed to synthesize the desired enediyne, which involves 
Sonogashira coupling reaction as a key step as shown in Scheme 1-6.59 
 
Scheme 1-6: Key synthetic step for the preparation of desired enediyne 
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Many attempts of this Sonogashira coupling reaction were unsuccessful in our hands, 
but careful analysis of the products formed during this reaction led to the discovery of 
a reaction where alkynes, one of the substrates of the Sonogashira reaction, undergo 
self oligomerization (dimerizarion, trimerization and tetramerization).  
 
1.5.2 Investigation of the self-oligomerization of terminal alkyne  
The reaction discovered while attempting the Sonogashira coupling reaction has 
applications for the synthesis of branched enediynes. Our objectives for this newly 
discovered reaction are  
i. To investigate the reaction components responsible for this reaction 
ii. To optimize reaction conditions for the trimerized products 
iii. To investigate its substrate scope.  
 
1.5.3 Reaction between (Z)-bromoalkenylpinacol boronates and 
terminal alkyne 
 
Since attempts of Sonogashira coupling reaction failed to generate the desired enediyne, 
another substrate, trisubstituted (Z)-bromoalkenylpinacol boronate, was prepared for 
sequential Sonogashira and Suzuki couplings. Surprisingly, attempts towards the 
sequential Sonogashira and Suzuki coupling reactions with these substrates led to the 
discovery of another interesting reaction, that is, a reaction between (Z)-
bromoalkenylpinacol boronates and alkynes to give an aromatized tetrasubstituted 
benzene. The objectives of this discovered reaction are  
i. To investigate the reaction components responsible for this reaction 
ii. To optimize reaction conditions for the aromatized products 
iii. To investigate the substrate scope 
iv. To investigate the reaction mechanism. 
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Chapter 2 
BODIPY as a versatile fluorophore 
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2.1 Introduction to fluorophores 
Fluorescence is a molecular property that allows molecules to emit light at lower 
frequencies upon exposure to higher frequencies of light.60 Fluorescence has a wide 
variety of applications in various research fields, such as molecular biology, 
biochemistry, medicine, and clinical diagnostics.61 The attachment of a fluorophore to 
a given biomolecule of interest, such as proteins and nucleic acids, can be used to image 
the accumulation of the molecule in specific organs of animals and human subjects.62 
Imaging of peptides or proteins can be performed by expressing fluorescent proteins 
(FP), which is achieved through the introduction of a gene encoding the fluorescent 
protein into the vectors. 63 , 64 , 65 , 66 , 67  However, using FP is burdened by a major 
disadvantage: the larger size of the introduced FPs may interfere with the intrinsic 
function of target proteins. In this arena, small fluorescent molecules are considered as 
potential candidates for imaging processes.   
A large number of small molecule fluorescent probes have been employed to 
investigate functions of biomolecules in the interior and exterior of cells. Small 
molecule fluorescent probes have certain advantages over large FPs, such as ease of 
functionalization, and easy tuning of emitting wavelength and intensity, which can be 
accomplished via chemical modifications.68 In addition, fluorescent molecules can be 
tuned to emit fluorescence in near infrared (NIR) regions, an alternative that can be 
used to avoid background fluorescence stemming from amino acids and other 
luminescent biomolecules.68 In addition to these advantages, temporal resolution can 
be attained by conjugating a fluorophore to the target of interest through application of 
a bio-orthogonal conjugation chemistry method.69,70 Considering the many applications 
and advantages of small molecule fluorophores, it is not surprising that there are many 
reports available on the literature concerning these compounds. Some of the most 
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widely used small molecule fluorophores include coumarin, fluorescein, BODIPY (4,4-
difluoro-4-bora-3a,4a-diaza-s-indacene), rhodamine, and cyanine dyes (Figure 2-
1).71,72 
 
Figure 2-1: Structures of fluorescent dyes 
 
In live-cell imaging applications, negatively charged fluorophores, such as 
fluorescein, are generally not considered as good candidates, as they lack the necessary 
cell membrane permeability needed to enter the cell. For such applications, cationic 
dyes such as rhodamine are generally considered as a better choice, as they generally 
possess good cell membrane permeability.73 However, the cationic and hydrophobic 
nature of rhodamine makes the compound prone to accumulation in the mitochondria 
or bind non-specially to proteins and lipids.73 Cyanine dyes, on the other hand, can be 
very useful in tissue imaging applications, as these molecules absorb NIR light, which 
can penetrate deeper into tissues without causing significant damage to the organism 
under study.74 In addition, the use of NIR fluorescence can also prevent the occurrence 
of background fluorescent interference related to tissue auto-fluorescence.74 However, 
while cyanine dyes contain good photo-physical properties, these molecules are 
characterized by lower photo-stability in comparison to rhodamine. As all fluorophores 
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are characterized by their own application-specific advantages and disadvantages, the 
development of new fluorophores is still a growing field of study. Within this context, 
BODIPY is considered a very useful skeleton for development of new fluorophores, as 
it possesses a number of advantages over other fluorescent molecules.  
 
2.2 BODIPY as a fluorophore 
BODIPY fluorophores are a class of molecules often applied for various imaging 
applications; as such, a considerable amount of academic attention has been given to 
the development of BODIPY-based fluorescent probes. The structure of the BODIPY 
core is shown in Figure 2-2. The IUPAC name of BODIPY is 4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene, a nomenclature similar to the all-carbon tricyclic s-indacene 
ring system. Rules for numbering any substituents on the BODIPY core structure are 
the same as for the carbon polycyclic structure.75  
 
Figure 2-2: Numbering scheme for BODIPY framework derived from indacene 
 
BODIPY-based fluorophores exhibit extraordinary photophysical properties, such as 
high molar extinction coefficients, high fluorescent quantum yields, and sharp 
excitation and emission peaks. BODIPYs are also relatively stable thermally, 
chemically, and photo-chemically, and are relatively insensitive to solvent polarity and 
pH. Due to these intriguing photophysical and photochemical properties, within the last 
two decades, tremendous research interest has been given to the creation of BODIPY-
27 
 
based fluorophores and BODIPY derivatives for a variety of applications such as laser 
dyes,76 fluorescent indicators, photodynamic therapy,77 and labeling of biomolecules.78 
Today, several BODIPY probes are commercially available, such as ER tracker Green 
and Lyso Tracker Red (Figure 2-3). 
 
Figure 2-3:  Commercially available BODIPY probes from Molecular Probes. 
 
2.3 Methodologies for the synthesis of BODIPY 
Due to its superior properties, the BODIPY skeleton has increasingly garnered the 
interest of synthetic chemists, leading to the development of several synthetic methods 
for the preparation of numerous BODIPY derivatives. Today, the majority of BODIPY 
compounds reported in the literature are fully substituted, mostly due to the instability 
of dipyrromethene, the precursor for unsubstituted BODIPY. A fully unsubstituted 
BODIPY core was first reported in 2009 by three independent groups.79,80,81 
The most commonly used method for the synthesis of BODIPY derivatives 
involves the treatment of acid chlorides (40) with pyrroles (39), yielding the unstable 
dipyrromethene hydrochloride salt (41), which further complexes with BF3OEt2 in the 
presence of a base such as Hünig’s base or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 
to give the desired BODIPY (42) (Scheme 2-1).82, 83  
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Scheme 2-1: Reagents and conditions: i) NEt3, i-Pr2EtN or DBU; (ii) BF3·Et2O, 
toluene or CH2Cl2. 
 
This method is suited for the synthesis of symmetrical BODIPYs. Using the 
same method, other electrophiles such as acid anhydrides and aldehydes have also been 
used as alternatives to the acid chlorides.84 Although isolation of unstable intermediates 
such as dipyrromethene hydrochlorides is quite difficult, the stability of this 
intermediate can be improved by increasing the number of C-substituents. 
Nevertheless, isolation of these intermediates is not necessary, and the intermediates 
can be treated with borontrifluoride dietherate directly for the boron complexation step.  
Synthesis of unsymmetrically-substituted BODIPYs should be followed by a 
different approach, in which condensation of carbonyl pyrrole (43) is treated with 
another pyrrole (44) having an unsubstituted α-position to give the corresponding 
dipyrromethene 45, which in turn is further treated with BF3·OEt2 in the presence of a 
base to give the desired BODIPY (46) (Scheme 2-2).85  
 
 
Scheme 2-2: Reagents and conditions: i) H+, CH2Cl2; ii) NEt3, BF3·Et2O 
 While BODIPYs have certain advantages, they are also associated with a few 
drawbacks that limit their applications, such as narrow Stoke’s shifts, poor water 
solubility, and lack of functional groups for conjugation.86,87,88,89 While these issues 
may be addressed with functionalized BODIPYs, major challenges exist to access those 
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functionalized BODIPYs, especially due to the limited availability of functionalized 
pyrroles. As such, the introduction of functional groups into the BODIPY core is an 
attractive way to access functional BODIPYs. The structural features of the BODIPY 
core, such as the positions of the substituent, π-electron conjugation, and structural 
rigidity, largely influence the fluorescent properties of the molecule. An increase in the 
π-electron conjugation of the BODIPY core leads to enhanced fluorescence emission, 
red-shifts in excitation and emission wavelengths. Increasing structural rigidity or steric 
constrains can aid in improving the quantum yields of the BODIPY compound, as 
smaller entropic losses are observed from the absorbed light energy.  
 
2.4 Functionalization of the BODIPY core 
2.4.1 Electrophilic substitution reactions 
Several functional groups have been introduced into the BODIPY core through 
electrophilic substitution reactions. Considering the mesmeric structures of the 
BODIPY core, the 2- and 6-positions possess the least positive charges, thus more 
prone to electrophilic attack (Figure 2-4). However, no definitive studies have been 
undertaken regarding the regioselectivity of these electrophilic substitution reactions, 
owing to the instability of BODIPY precursors. 
 
 
Figure 2-4: Mesomeric structures of BODIPY core 
 
Electrophilic substitution reactions have been reported with the BODIPY core 
including sulfonation, nitration and halogenation. Sulfonation of pentamethyl BODIPY 
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(47) was performed by treatment with chlorosulfonic acid, followed by neutralization 
with a base (Scheme 2-3).82 This sulfonated BODIPY dye (48) was shown to exhibit 
strong fluorescence in water or MeOH, and is more stable than parent BODIPYs.  
Nitration of BODIPY was performed with nitric acid; in this work, the introduction of 
nitro groups was observed to quench the fluorescence of BODIPY (47), and drastically 
reduce quantum yields (Quantum yield of 0.73 for 47, 0.31 for 49).90 
 
 
Scheme 2-3: Sulfonation and nitration of BODIPY 
 
Electrophilic bromination of the penta-substituted BODIPY (47) was performed 
with bromine (Scheme 2-4). The brominated compound (50) was shown to exhibit a 
red shift in the emission spectra, as well as lower quantum yields due to the heavy atom 
effect.91 An iodo-BODIPY was obtained by treating BODIPY (51) with iodine in the 
presence of HIO3. The resulting iodo-BODIPY (52) was shown to be highly resistant 
to photo bleaching and was found to be an efficient photosensitizer.92  
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Scheme 2-4: Halogenation of BODIPY 
 
 Halogenated BODIPYs are of particular interest, as these compounds allow for 
the introduction of a variety of functionalities onto the BODIPY core.93 Halogenated 
BODIPYs are also versatile precursors for several palladium-based cross-coupling 
reactions such as Stille, Negishi, Heck, Suzuki, and Sonogashira. Fine tuning of the 
optical properties of BODIPY can be achieved by introducing functional groups with 
the aid of nucleophilic substitutions on halogenated BODIPYs. A 2,6-halogenated 
BODIPY core can be obtained with the use of various reagents, such as N-
chlorosuccinimide (NCS), N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), Br2, 
I2 through electrophilic substitution reactions.
94,95 In comparison to the other positions, 
such as 3, 5, 7, 8, halogenations at the 2, 6 positions can be easily accomplished due to 
the least positive charges present in the latter positions (Figure 2-3). BODIPYs 
halogenated at 3, 5, 7, 8 can be obtained from halogenated dipyrromethane core or 
halogenated pyrroles. For example Dehaen and Boens developed a method to obtain 3- 
and/or 5-chloro BODIPYs (55, 58) either by the treatment of dipyrromethane core (53) 
with NCS to give the chlorinated dipyrromethane (54) and followed by oxidation and 
boron complexation, or by taking the chlorinated pyrrole precursors (57) which were 
obtained by the chlorination of pyrrole (56) with NCS (Scheme 2-5).96,97,98,99 
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Scheme 2-5: Synthesis of 3, 5-chloro substituted BODIPYs 
 
Recently, Zhou et al. reported regioselective halogenation by treatment of 
meso-aryl, meso-H, and meso-alkyl substituted pyrroles (60) with copper halides 
(Scheme 2-6). The number of substitutions (mono- or di-) was controlled by the 
equivalents of the copper halide reagent.100 While the treatment of BODIPY with CuCl2 
gives the 3, 5-chloro substitutions (59, 61), treatment of BODIPY with CuBr2 gives the 
2, 6-bromo substitutions. This difference in the regioselectivity of the halogenation with 
different types of copper halides is attributed to the different mechanistic pathways of 
the halogenation process.100 
 
Scheme 2-6: 3, 5 selective chlorination of BODPY with CuCl2 
 
Mechanistic investigations performed to understand the chlorination reaction 
revealed that chlorination of BODIPY likely occurs through a cation radical pathway 
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in the single-electron transfer (SET) process followed by a nucleophilic addition by the 
chloride anion. The bromination reaction, on the other hand, is believed to operate 
through the generation of molecular bromine from the oxidation of bromide anion, 
leading to the electrophilic substitution reaction to give brominated BODIPY 
derivatives. Attempts for chlorination of BODPY with other metal chlorides such as 
includes ZnCl2, MgCl2, FeCl3, AlCl3, and TiCl4 did not lead to the formation of any 
chlorinated BODIPY. 100  
 
2.4.2 Nucleophilic substitutions of halogenated BODIPYs 
Halogenated BODIPYs (55) have been used for further functionalization through 
nucleophilic substitution reactions by nucleophiles such as alkoxides, thioalkoxides, 
amines (piperidine, aniline, N-methyl aniline), and diethylmalonate (O, N, S, and C 
centered nucleophiles) (Scheme 2-7).97,98 
 
Scheme 2-7: Nucleophilic substitution of 3 and 5-chlorinated BODIPY 
These nucleophilic substitution reactions can be used to obtain either mono- or 
di-substituted BODIPYs (62) by altering the reaction conditions. While stirring the 
dihalo BODIPY with two equivalents of nucleophile at room temperature gives the 
monosubstituted product, treatment of dihalo BODIPY with four equivalents of 
nucleophile under reflux in acetonitrile provided the di-substituted product. Two 
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different nucleophiles can be introduced one after another using similar conditions. 
Nucleophilic substitutions at the 3, 5 positions can effectively alter the absorption and 
emissions spectra of parent dihalo-BODIPY (55). For example, amino- and thio-
substituted BODIPYs have been shown to exhibit a red shift in both absorption and 
emission spectra. One of the BODIPY derivatives synthesized by sequential 
nucleophilic substitution with methoxide and azacrown ether act as a potassium 
selective ratiometric fluorescent indicator.98  
Nucleophilic substitution reactions have also been explored at the meso-position 
of BODIPY. Biellmann et al. reported BODIPY derivatives with sulfur- containing 
leaving group at the meso-position for the nucleophilic substitution reactions (Scheme 
2-8). 101  The synthesis of these sulfur-containing BODIPYs was performed by the 
treatment of pyrroles (63) with thiophosgene to provide the thioketone (64) which was 
then treated with electrophilic reagents such as methyl iodide or isopropyl triflate to 
give the corresponding dipyrromethene (65). Subsequent complexation of 
dipyrromethene (65) with BF3·OEt2 in the presence of Et3N afforded the final thio-
containing BODIPY derivative (66).  
 
Scheme 2-8: Synthesis of 8-alkylthio-BODIPY 
 
These thio BODIPY derivatives were treated with aniline for the nucleophilic 
substitution reaction to give 8-arylamino-BODIPY compounds.101 In an interesting 
study 8-methylthio-BODIPY (66a) was shown to have ratiometric fluorescent behavior 
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towards mercury ions. Thus, fluorescence emission from a solution of 8-methylthio-
BODIPY (66a) changed from bright green to blue upon addition of HgCl2.  This 
fluorescent shift was explained by the Hg2+ promoted displacement of methylthio with 
water to convert the 8-methylthio- to 8-hydroxy-BODIPY (68) through an intermediate 
compound 67, which will leads to the changes in both the absorption and emission 
wavelengths of the 8-methylthio BODIPY (Scheme 2-9).102  
 
Scheme 2-9: Mechanism of mercury ion detection by 8-methylthio-BODIPY 
 
Nucleophilic substitutions have also been performed on the halogenated side 
chain of the BODIPY (70) at the meso-position (Scheme 2-10).103,104 Thus, halogenated 
BODIPYs (70), which can be readily prepared by the treatment of pyrrole (69) with 
halogenated acyl chloride, have been treated with several nucleophiles to give various 
substituted BODIPYs (71). Some of the most notable compounds made in this approach 
include azacrown ether conjugated BODIPY compounds, which are known to act as 
metal ion sensors by the PET mechanism.103 
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Scheme 2-10: Nucleophilic substitutions on the halogenated side chain at the meso- 
position of BODIPY 
 
2.4.3 Palladium catalyzed functionalization of BODIPY compounds 
Halogenated BODIPY derivatives (55) have been successfully used as precursors for 
palladium catalyzed coupling reactions, allowing access to functionalized BODIPY 
compounds.105 This approach opens up new pathways towards the derivatization of the 
BODIPY core with various functional groups such as aryl, ethenylaryl, and ethynylaryl 
through the use of various coupling reactions such as Stille, Suzuki, Heck, and 
Sonogashira couplings (Scheme 2-11). BODIPY compounds 72 and 73 derived by 
these coupling reactions are characterized by extended conjugations, and contain a 
range of absorption and emissions wavelengths. Mono-substituted BODIPYs can be 
further derivatized into unsymmetrical BODIPYs either by nucleophilic substitutions 
or by another palladium coupling reaction.105 
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Scheme 2-11: Coupling reaction of halogenated BODIPYs 
 
Palladium-catalyzed coupling reactions have also been used for the C-H 
functionalization of the BODIPY core at the 2, 6 positions (Scheme 2-12). This method 
allows for direct access to functionalized BODIPY derivatives, without the need for use 
of halogenated BODIPY precursors.106 The BODIPY compound 51 was derivatized 
with unsaturated esters, acids, sulfonic acids by a palladium catalyzed oxidative 
coupling to give either mono- or di-substituted BODIPY derivatives 74 and 75, 
respectively.106 
 
Scheme 2-12: C-H functionalization of BODIPY 
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2.4.4 Condensation reactions 
Methyl substitutions at the 3, 5 positions of BODIPY are known to have enough acidity 
to participate in nucleophilic addition and condensation reactions, such as Knoevenagel 
reactions. Accordingly, the reactivity of these methyl groups can be utilized to make 
styryl compounds through application of condensation of BODIPY with aromatic 
aldehydes. Akkaya et al. synthesized styryl substituted BODIPYs (77, 78) by the 
condensation of 3, 5-methyl groups of BODIPY 76 with aromatic aldehyde (Scheme 
2-13).107 This condensation method is very useful for the derivatization of BODIPY to 
extend the conjugation and to tune the absorption and emission wavelengths of 
BODIPY core. 
 
Scheme 2-13: Condensation of BODIPY with an aldehyde 
 
2.4.5 C-H activation 
In addition to various methods, C-H activation at 3,5-positons is an alternative method 
for the functionalization of the BODIPY core. Dehaen et al. reported functionalization 
of BODIPY dyes by oxidative nucleophilic hydrogen substitution at the 3,5-positions 
(Scheme 2-14). Thus, BODIPY 79 was treated with C and N nucleophiles followed by 
oxidation by oxygen to give the corresponding substituted BODIPY derivatives 80 in 
excellent yields.108  
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Scheme 2-14: Oxidative nucleophilic hydrogen substitution of BODIPY 
 
   While the nucleophilic substitution can be easily performed with 3,5-
halogenated BODIPYs as halogens act as leaving groups, it is not possible to carry out 
nucleophilic substitution reactions with non-halogenated BODIPYs without an 
oxidation step. Generally electron poor aromatic rings of BODIPYs are prone to 
undergo nucleophilic attack at activated positions by forming a σ-H adduct (81). Since 
hydride in this adduct is a poor leaving group, oxidation is required to re-establish the 
aromaticity (Scheme 2-15). 
 
Scheme 2-15: Mechanism for the oxidative nucleophilic substitutions 
 
In another report Dehaen et al. showed a radical based C-H arylation of the 
BODIPY core with aryl diazonium salts which are known to generate radicals through 
heterolytic dediazoniation mechanism (Scheme 2-16). Thus, reactions between meso-
arylated BODIPY (79) and various aryldiazonium salts (81) in the presence of a catalyst 
FeCp2 yielded exclusively 3- or/and 5-aryl substituted BODIPYs (82).
109 
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Scheme 2-16: C-H arylation of BODPYs with aryldiazonium salts 
 
The catalyst was found to lose its activity due to the arylation of newly formed 
ferricinium ions, resulting in the formation of phenylferrocene and diphenylferrocene. 
To overcome this problem the catalyst was replenished by continuous addition at a flow 
rate 0.2 mmol/h to maintain its presence in the reaction mixture. The selectivity for the 
3, 5-positions was attributed to the stability of the radical sigma complex formed after 
the reaction of BODIPY and aryl radical. The addition of aryl radical at the 3-position 
of one of the pyrrole would generate a radical stabilized by conjugation over several 
double bond and the electron withdrawing effect of imine in the other pyrrole due to 
the complexation to the strongly polarized BF2 (Scheme 2-17).  
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Scheme 2-17: Mechanism for C-H arylation of BODIPY 
 
2.5 Functional groups on the BODIPY core for conjugation purposes 
BODIPY derivatives synthesized for conjugating to the biomolecules such as proteins 
have found many applications in the imaging of biological systems such as localizing 
proteins and small molecules of interest in living cells. For example Meijler et al. used 
an aminooxy-BODIPY to localize an intracellular bacterial receptor involved in cell-
to-cell communication in Pseudomonas aeruginosa cells. 110  In another study a 
fluorogenic tetrazine-BODIPY was used to track an anticancer drug taxol in live cell 
imaging.111 Due to the number of interesting bio-imaging applications of BODIPY-
conjugates, many BODIPY derivatives with functional groups, such as succinimidyl 
esters, sulfonyl chlorides, isothiocyanates, alkynyls, and azides, have been synthesized 
to conjugate a target of interest, leading to the formation of amide, sulphonamide, 
thiourea and other conjugates. Depending on the available functional group on the 
BODIPY and the target, several methods may be available for the conjugation of 
BODIPY to the desired molecule.  
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2.5.1 Succinimidyl esters 
N-Hydroxysuccinimide (NHS) ester is the most commonly used functionality for 
conjugation of BODIPYs to amine-containing target compounds such as proteins. This 
methodology has been widely used for the labelling of proteins with various targets, 
including radioactive isotopes such as iodine-125, tritium, and carbon-14, as well as 
fluorescent molecules such as fluorescein and BODIPY.112,113,114 Succinimidyl esters 
react with amines, forming an amide bond and producing N-hydroxy succinimide as a 
leaving group (Scheme 2-18). These conjugation reactions are generally quite efficient, 
requiring 30 min to 4 hrs in water–DMSO at room temperature for conjugation to 
complete.  
 
 
Scheme 2-18: Amine labelling with succinimidyl ester 
 
Numerous BODIPY derivatives containing the succinimidyl ester reacting group have 
been synthesized by both academic and industrial research groups. The first synthesis 
of the BODIPY-succinimidyl ester was reported in a 1988 patent by Molecular Probes 
(now part of Life Technologies - Thermo Fisher Scientific).91 Synthesis of the 
BODIPY-succinimidyl ester was performed by the coupling of an ester-substituted 
pyrrole (84) with a pyrrole carboxyaldehyde (83) to give a dipyrromethene, which was 
further complexed with BF3OEt2 to generate a BODIPY derivative having an ethyl 
ester (85). This ester was hydrolyzed in the presence of a base to give a carboxylic acid, 
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and subsequently coupled with N-hydroxy succinimide (NHS) to yield NHS conjugated 
BODIPY derivatives (86) (Scheme 2-19).  
 
 
Scheme 2-19: Synthesis of BODIPY-succinimidylester 
 
In an application of BODIPY-succinimidyl ester, a conjugated protein was used to 
measure the activity of proteases by fluorescent assay. 115 Initially, the BODIPY was 
conjugated to a small protein casein, which is a substrate for several endoproteases. 
Labelling of casein with multiple BODIPY can lead to “autoquenching” by the adjacent 
fluorophores. Upon cleavage of casein by protease, the initially linked fluorophore is 
released, enhancing the signal. The degree of signal enhancement can then be used as 
a measurement for protease activity. 
 
2.5.2 Isothiocyanate BODIPY dyes  
Owing to the electrophilic nature of center carbon, isothiocyanate is very reactive 
towards nucleophiles such as amines. The nucleophilic attack of an amine on 
isothiocyanate results in the formation of a thio-urea linkage (Scheme 2-20).  
Scheme 2-20: Amine labelling with isothiocyanate 
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Similar to the BODIPY-succinimidyl ester, the first synthesis of the BODIPY-
isothiocyanate derivative was reported in a Molecular Probes patent in 1988.91 In this 
patent, the BODIPY-succinimidyl ester was reported as a starting material for the 
synthesis of the BODIPY-isothiocyanate. Thus, the BODIPY-succinimidyl ester (87) 
was reacted with ethylenediamine to yield the amino-amido-BODIPY, which was 
converted to BODIPY-isothiocyanate (88) with the use of thiophosgene (Scheme 2-
21).  
 
 
Scheme 2-21: Synthesis of BODIPY-isothiocyanate 
 
Following a similar approach, Meltola et al. synthesized a BODIPY-succinimidyl ester 
having an aromatic thiocyanate group (Scheme 2-22).116 For this purpose, a BODIPY 
(90) consisted of two propionic acid substituents was first obtained from condensation 
of tetrasubstituted pyrrole (89). One of the free carboxylic acid groups was activated 
by treatment with N-hydroxysuccinamide. The activated carboxylic acid was then 
reacted with 4-(2-aminoethyl)-aniline to yield a BODIPY derivative with a free amino 
group. The resulting compound was subsequently treated with thiophosgene in a basic 
medium to give the BODIPY dye with isothiocyanate functionality (91) 
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Scheme 2-22: Synthesis of BODIPY-isothiocyanate 
 
This synthesized BODIPY-isothiocyanate was then conjugated to IgG antibody by 
incubating a 10-fold excess of BODIPY-isothiocyanate with IgG. In this application, 
the conjugation of isothiocyanate derivatives was noted to be less efficient in 
comparison to conjugation with succinimidyl esters.  
 
2.5.3 Iodoacetamide BODIPY dyes 
Iodoacetamides are well-known compounds in conjugation chemistry, and are widely 
recognized to be very reactive towards the sulfhydryl groups.117 Since the methylene 
group in iodoacetamide is attached to a carbonyl and an iodide, it reacts in an 
electrophilic manner with nucleophiles (Scheme 2-23).  
 
 
Scheme 2-23: Labeling of thiol with iodoacetamide 
Although iodoacetamides are very reactive with the sulfhydryl groups of cysteine, they 
are also reactive with other functionalities present in amino acids side chains, in the 
following decreasing order of reactivity: imidazolyl of histidines, thioether of 
methionines and amines from lysines. Selectivity of iodoacetamides for sulfhydryl 
groups can be improved by reducing the amount of iodoacetamide, or by increasing the 
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basicity of the reaction mixture to an alkaline pH. Synthesis of BODIPY-iodoacetamide 
derivatives was performed in a manner similar to the synthesis of isothiocyanates 
(Scheme 2-24). First, a BODIPY-succinimide ester 92 was reacted with a free amine 
from cadaverine to yield a BODIPY containing a trifluoroacetamide function (93). The 
trifluoroacetamide was then converted to a free amine, and reacted with a para-
nitrophenyl iodoacetate to give the BODIPY-iodoacetamide derivative (94).  
 
 
Scheme 2-24: Synthesis of BODIPY iodoacetamides 
 
The obtained BODIPY-iodoacetamide derivative 94 was then used to label the protein 
plasminogen activator inhibitor I, which modulates fibrinolytic activity in human 
blood.118 This allowed for the discovery and further study of important interaction sites 
responsible for the inhibition 
2.5.4 Maleimide BODIPY dyes  
Maleimide is a well-known functional group in conjugation chemistry. Maleimides are 
very reactive Michael acceptors; they react rapidly and specifically with sulfhydryl 
groups through Michael addition reactions, in spite of the presence of amines and 
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hydroxyls (Scheme 2-25).119 Due to this useful reactivity, BODIPY-maleimides have 
been used extensively to label the cysteine residues of proteins.120 
 
 
Scheme 2-25: Labelling of thiol with maleimide 
 
The synthesis of the BODIPY-maleimide derivative was first initiated by reacting a 
BODIPY-succinimidyl ester (95) with ethylenedimine (Scheme 2-26). Next, the free 
amino group was reacted with a cross linking agent, N-succinimidyl maleimidoacetate 
to give the BODPY-maleimide 97.121 BODIPY-maleimide derivatives such as 97 have 
been applied in the development of a fluorimetric assay used to quantify reactive thio 
groups of proteins such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In 
this study, incubation of the BODIPY-maleimide derivative 81 with GAPDH in an ice 
bath for 4 hours in a phosphate buffer resulted in a BODIPY conjugated GAPDH.122  
 
Scheme 2-26: Synthesis of BODIPY-maleimide derivative 
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In another approach, three isomeric BODIPY-maleimide derivatives were synthesized 
by using BODIPYs containing aniline at the meso-position (Scheme 2-27). 123 
BODIPY-aniline derivatives (100) were obtained from reduction of nitro BODIPYs, 
which were obtained using a classical BODIPY synthesis process. This process 
included the treatment of 2,4-dimethylpyrrole (99) with nitrobenzaldehyde (98), 
followed by aromatization with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) and 
complexation with BF3OEt2. BODIPY-derived aniline (100) was reacted with maleic 
anhydride to form BODIPY-maleic acid (101), which was subsequently converted to 
BODIPY-maleimide (102) by dehydrative cyclization. The same method was used for 
the synthesis of three substitutional isomers of BODIPY derivatives.123  
 
 
Scheme 2-27: Synthesis of BODIPY-maleimide derivatives 
 
Among the three substitutional isomers of 102, the ortho compound has been 
shown to have the lowest fluorescence, probably due to the photo-induced electron 
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transfer phenomenon. Interestingly, a product from the reaction of this ortho isomer of 
BODIPY-maleimide with free thiols was shown to restore BODIPY fluorescence. This 
is likely due to loss of the double bond in maleimide, which prevents electron transfer, 
thus restoring fluorescence. 
 
2.5.5 Thiosulfate and thiosulfonate BODIPY dyes 
Thiosulfate and thiosulfonate functional groups have been widely used to conjugate 
proteins with fluorescent probes. 124 , 125  Thiosulfates and thiosulfonates differ from 
sulfates and sulfonates; in the former compounds, one of the oxygen atoms is replaced 
with a sulfur, making the compound more reactive towards nucleophilic attack from 
compounds such as thiols (Scheme 2-28). An interesting feature of these functional 
groups is the reversibility of the disulfide bond generated after conjugation to the 
protein through the sulfhydryl moiety of cysteine. 
 
Scheme 2-28: Labelling of thiols with thiosulfate and thiosulfonates 
These disulfide bond can be cleaved (reduced) by reducing agents such as dithiothreitol 
(DTT) and tris(2-carboxyethyl)phosphine (TCEP). The synthetic strategy followed for 
the synthesis of BODIPY-thiosulfate derivatives is shown in Scheme 2-29. 126  A 
carboxylic acid with thiosulfate functionality (104) was obtained through a reaction of 
bromoacetic acid (103) and sodium thiosulfate, and subsequently reacted with 1,2,4,5-
tetrafluorophenyl ester DIPEA, yielding a thiosulfate transferring reagent (105).  A 
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BODIPY bearing an amino group (106) was then reacted with the thiosulfate 
transferring reagent to attain the final BODIPY-thiosulfate (107).126 
 
 
Scheme 2-29: Synthesis of BODIPY-thiosulfate 
 
Several methods have been reported to prepare BODIPY-methanethiosulfonate 
derivatives. For example, a trisubstituted pyrrole (69) was treated with chloroacetyl 
chloride (108) to yield dipyrromethene, which was then complexed with BF3OEt2 in 
the presence of triethylamine to give a chloro BODIPY (109). The chlorine was 
replaced with iodine by treatment with sodium iodide, yielding an iodo-BODIPY (110), 
which was then reacted with sodium thiosulfonate to attain the BODIPY 
methanethiosulfonate (111) (Scheme 2-30 A).127 
 
Scheme 2-30: Synthesis of BODIPY-methanethiosulfonate 
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In another method, a BODIPY bearing N-hydroxysuccinimide (112) was treated 
with 3-aminopropyl methanethiosulfonate hydrobromide (113) in the presence of 
diisopropylethylamine (DIPEA), resulting in the formation of BODIPY-
methanethiosulfonate (114) (Scheme 2-30 B).128  
BODIPY-methanethiosulfonate has been used in many applications of protein 
labelling. For instance, this fluorescent probe was attached to the photosynthetic 
complex CP29, with the aim to study the structure of the N-terminal domain of the 
complex with the use of fluorescence resonance energy transfer (FRET). 129 For this 
purpose, several proteins with single amino acid mutations were synthesized by 
replacing each amino acid in the N-terminal domain with cysteine residues. After 
conjugation with BODIPY-methaenthiosulfonate, FRET experiments were carried out 
to study the interactions of labelled amino acid with other amino acids in order to 
constitute the structure of N-terminal domain. 
 
2.6. Bio-orthogonal labeling of biomolecules  
In addition to classical conjugating functionalities, which can be used to react with 
amino acids of proteins, bio-orthogonal conjugation has become a valuable approach 
for protein modification. In this approach, a specific functional group is incorporated 
into the protein to react with a specific functional group present on the other conjugating 
partner, such as a fluorophore.  
2.6.1 BODIPY-hydrazine, hydrazide or aminooxy compounds 
An extensively explored bio-orthogonal approach involves the conjugation of a 
nitrogen nucleophile, such as hydrazine, hydrazide, or hydroxylamine, to the carbonyl 
functionalities (Scheme 2-31).130 These carbonyl functionalities can be incorporated 
into proteins either via chemical modifications, or through genetic manipulation, such 
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as insertion of para-acetyl-phenylalanine or post-translational enzymatic modification 
of glycine to formaldehyde. While the reaction of carbonyls with hydrazine and 
hydrazide generates hydrazine linkages, the reaction with hydroxylamine generates 
oxime linkages.131 
 
Scheme 2-31: Labelling of aldehydes or ketones with hydrazide, hydroxylamine or 
hydrazide 
 
BODIPY-hydrazide derivative (118) was synthesized by treating hydrazine 
hydrate with BODIPY ethyl ester (117), which was accessible by the reaction of 
pyrrole-2-carboxaldehyde (116) and a pyrrole containing ester functionality (115), 
followed by complexation with borontrifluoride (Scheme 2-32).91  
 
 
Scheme 2-32: Synthesis of BODIPY-hydrazide 
 
In another method, BODIPY-hydrazide (121) was synthesized by inducing 
condensation of hydrazine with the BODIPY-carboxylic acid derivative (120), which 
was obtained from the reaction of dimethyl pyrrole (99) with a cyclic anhydride (119) 
(Scheme 2-33).132  
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Scheme 2-33: Synthesis of BODIPY-hydrazide 
 
BODIPY-hydrazine derivatives (124) have been synthesized by nucleophilic 
substitution of chlorinated BODIPY (122) with hydrazine. 133  Depending on the 
equivalents of hydrazine present for nucleophilic substitution, either mono- or 
dihydrazine BODIPYs will be obtained. The mono hydrazine-substituted chloro-
BODIPY (123) was treated with various nucleophiles in order to obtain a library of 
BODIPY-hydrazine derivatives (Scheme 2-34).133 
 
Scheme 2-34: Synthesis of BODIPY-hydrazide 
 
A hydroxylamine BODIPY (129) was synthesized by using an amine-
containing BODIPY precursor. 134  The BODIPY precursor used in this case was 
obtained through reduction of nitro BODIPY (126), which was in turn prepared using 
the condensation of dimethyl pyrrole (99) and nitro aldehyde (125). Next, an amino-
BODIPY (127) was coupled to the phthalimido-aminooxyacetic acid through an amine. 
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Finally, the phthalimide group of compound 128 was deprotected to give the 
hydroxylamino-BODIPY (129) (Scheme 2-35).134 
 
 
Scheme 2-35: Synthesis of BODIPY-hydroxylamine 
 
 
2.6.2 Azide alkyne click reaction 
Another important bioorthogonal strategy in conjugation chemistry involves the 
cycloaddition of azide and alkynes. This cycloaddition reaction, often termed a Click 
reaction or Huisgen cycloaddition, occurs via a concerted mechanism to generate a 
stable 1,2,3-triazole linkage (Scheme 2-36). Click reaction has been widely applied in 
the field of bio-imaging for various applications.135,136 
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Scheme 2-36: Conjugation of BODIPYs through alkyne-azide click reaction 
 
Generally, this reaction is performed by using a metal-catalyst such as CuI. However 
catalysts can be eliminated by using highly reactive alkynes such as strained 
cyclooctyne. There are several ways to incorporate either alkynes or azides into 
BODIPYs; the method chosen is dependent on the purpose of its application. The most 
commonly used methods to generate BODIPY alkynes (132) or azides (133) include 
the use of BODIPY substrates with halogenated side chains (131), which can be 
obtained through a reaction of BODIPY (130) with NBS. Nucleophilic displacement of 
the halide with either sodium azide or propargyl alcohol can then be used to generate 
azido and alkyno BODIPYs (Scheme 2-37).137  
 
 
Scheme 2-37: Synthesis of BODIPY-alkyne and azides 
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2.6.3 Tetrazene-alkene click reaction 
Inverse-electron-demand Diels–Alder (IEDDA) tetrazene cycloaddition is yet another 
click reaction introduced for bioorthogonal conjugation. Unlike normal Diels-Alder 
reactions, in IEDDA, the reaction occurs between electron-poor diene and electron-rich 
dienophile.138,139 BODIPY-tetrazine can be efficiently conjugated to various partners 
having functional groups such as 1-methylcyclopropenes, norboranes, trans-
cyclooctene, and cyclooctynes through IEDDA cycloaddition.  
Tetrazene moieties act as chromophores as they absorb light in the visible 
region. As such, when tetrazenes are attached to fluorophores such as BODIPYs, they 
act as a fluorescent quencher. Depending on how the tetrazene is attached to the 
BODIPY, fluorescence quenching of the BODIPY can occur by energy transfer through 
space, namely fluorescence resonance energy transfer (FRET), through a bond, as well 
as by both. However, upon reaction of BODIPY-tetrazene with an alkene, fluorescence 
is restored due to changes that occur in both the electronic and structural properties of 
BODPY-tetrazene. Thus, BODIPY-tetrazene can be used as a turn-on fluorescent 
probe. A green-light-emitting BODIPY (134) having a tetrazene through a spacer 
exhibited 15-fold increased fluorescence upon reaction with trans-cyclooctene to form 
compound 135.140,141 
 
 
Scheme 2-38: Reaction of BODIPY-tetrazine with cyclooctene 
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In another report, non-fluorescent BODIPY molecules (137, 140 and 142) were 
synthesized with their fluorescence quenched by through bond resonance energy 
transfer. Compounds 137 and 140 were synthesized through a reaction of hydrazine 
hydrate with the corresponding cyanophenyl-BODIPY (136 and 139) in the presence 
of zinc triflate, followed by oxidation with sodium nitrate and hydrochloric acid. 
Compound 142 was synthesized by coupling of a tetrazine derivative with 2-iodo-
pentamethyl BODIPY (Scheme 2-39).142 
 
Scheme 2-39: Reaction of substitutional isomers of BODIPY-tetrazine with trans-
cyclooctene 
 
Conjugation of these compounds with trans-cycloocetene exhibited dramatic 
fluorescence enhancement upon the formation of 138, 141 and 143. Reaction of 
compound 136 with trans-cyclooctenol in water gave a 900-fold turn-on ratio of 
fluorescence, while its substitutional isomer compound 140 yielded a 1600 fold turn-
58 
 
on ratio. Surprisingly, compound 142 was shown to only exhibit a 120-fold turn-on 
ratio.142 
 
2.7 General perspectives and objectives of the present work 
The development of new methods capable of introducing particular 
functionalities into the BODIPY core can aid in improved access to BODIPYs with 
desired properties. In this arena, we discovered and developed mild reaction 
conditions to introduce various useful functional groups into the BODIPY core by 
treatment of BODIPY with cupric nitrate pentahydrate. The work presented in this 
thesis includes the following objectives: 
i. To optimize conditions for the introduction of a particular functional group, such as 
hydroxyl, aldehyde, nitro, or nitromethane 
ii. To investigate the effect of water content of the reaction mixture on the outcome of 
reaction 
iii. To broaden the scope of this chemistry by treatment with various metal salts, 
especially copper salts 
iv. To synthesize BODIPY-sugar conjugates through the click chemistry 
v. To characterize the liposomes formed by the BODIPY-sugar conjugates. 
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Chapter 3 
Results and Discussions 
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3.1 Homotrimerization and tetramerization of 
terminal alkynes 
 
Enediyne functionality is known to be the pharmacophore in several natural products, 
and has been shown to target DNA, leading to their anti-microbial and anti-cancer 
properties (discussed in Chapter 1). The aim of the current project is to attach enediyne 
functionality to DNA in order to investigate its site-specific DNA cleavage properties. 
We have hypothesized that a single strand DNA having enediyne functionality would 
be useful for site-specific cleavage of target DNA. When the DNA strand containing 
enediyne functionality (“guide sequence”) binds to the target DNA through Watson-
Crick base pairing, the enediyne functional group comes into close proximity to the 
target DNA. The activation of enediyne then leads to the formation of benzenoid 
radicals by a Bergmann cyclization mechanism. The newly formed benzenoid radicals 
are capable of stripping hydrogen atoms from the sugar moieties of the target stand, 
leading to cleavages of the target DNA (Figure 3-1).  
 
 
Figure 3-1: Cleavage of target DNA by enediyne 
 
  Since enediyne is preorganized in a specific nucleobase position of DNA 
through the sequence complementarity between the target and guide sequences, it will 
be possible to achieve site-specific cleavages of DNA. The attachment of enediyne 
functionality to DNA can be achieved through post-synthetic modifications. For 
R
R'
R
R'
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instance, an oligonucleotide having a cyclooctyne at 5’ terminus will be synthesized by 
coupling the bicyclo[6.1.0]nonyne (BCN) phosphramdite (145) as a final coupling 
cycle during the solid-phase synthesis of oligonucleotide.143 After purification, the 5’-
cyclooctyne modified oligonucleotide will be treated with compound 144 to 
incorporate an enediyne at the 5’-terminums of the oligonucleotide through an azide-
alkyne cycloaddition (click reaction).143  
 
 
Figure 3-2: Designed enediyne phosphoramidite 
 
           As highlighted in compound 144 (Figure 3-2), each functionality of the 
molecule has specific purpose. The azido functional group on the side chain of enediyne 
is needed for the incorporation of this molecule into DNA through Click reaction. The 
enediyne functional group is required for the cleavage of the target DNA strand. 
Another important functional group that has been designed into this molecule is an 
aldimine (Schiff base). Here, the Schiff base formed by the amine and pyridine-2-
aldehyde would serve as a trigger for the activation of enediyne for cyclization. Upon 
binding of the Schiff base to a metal ion, the distance between the two acetylene bonds 
in the enediyne is decreased, lowering the activation barrier of the Bergman cyclization 
temperature to room temperature. Zaleski et al. reported an enediyne containing a Shiff 
base at both termini of the acetylene bonds which underwent for the Bergmann 
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cyclization at room temperature in the presence of magnesium chloride58with a half-
life of cyclization reaction of 2.2 h as estimated by NMR. This literature observation 
serves as the basis for our approach towards the Bergman cyclization-mediated DNA 
cleavages. 
 
3.1.1. Synthesis of the designed substituted enediynes  
The strategy for the synthesis of the desired substituted enediyne is shown in Scheme 
3-1. The synthesis was initiated through treatment of 3-buyne-1-ol 146e with boron 
trimbromide, followed by hydrolysis to produce bromovinylboronic acid 147 in 45% 
yield. The bromovinylboronic acid 147 was then converted to potassium salt 148 in 
55% yield by the treatment with potassium dihydrofluoride. The resulting potassium 
trifluoroborate 148 was then subjected to bromodeborination by treatment with 
tetrabutylammoniumtribromide (TBAT) to produce cis-dibromoalkene 37 in 70% 
yield.  
 
Scheme 3-1: Reagents and conditions: a). i. BBr3, Dry DCM, 0°C–rt, 3 h. ii. H2O, rt; 
b). KHF2, MeOH–H2O, rt, 3 h; c). TBAT, THF-H2O, rt, 3h; d). N-Boc-propargylamine, 
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Pd(PPh3)4, CuI, dry benzene, 45 °C, 10 h; e). i. TFA, ii. pyridine-2-aldehyde, AcOH. 
f). i. MsCl, pyridine, ii. NaN3, DMF. 
 
The next key step in this strategy involved the introduction of two alkyne 
substituents to cis-dibromoalkene 37 in a single step under Sonogashira coupling 
reaction conditions (Pd-catayst, CuI, and a base). Unfortunately, all attempts to produce 
the desired enediyne from the reaction between dibromoalkene (37) and N-Boc-
propargylamine under various conditions were unsuccessful. While there are several 
reports in the literature detailing the use of the Sonogashira coupling reaction for the 
vicinal dihalides,144,145,146 most of the reports used aromatic halides as substrates, with 
very few reports detailing the successful use of vinyl halides, especially aliphatic 
halides having side chains.147,148 ,149  In order to investigate the reasons behind the 
unsuccessful attempts, reactions were performed between N-Boc propargylamine 146a 
and dihaloalkenes with various side chains 150 (Scheme 3-2A). None of these reactions 
produced desired Sonogashira-coupled products. As a starting point, it was speculated 
that the hydroxyl group on the side chain might bind to and inactivate the catalysts, 
leading to unsuccessful Sonogashira coupling reactions. To investigate this hypothesis, 
the hydroxyl group was protected with TBDMS, and the coupling reaction was 
attempted. However, the attempt failed to yield Sonogashira-coupled product 151. In 
the next attempt, two dihaloalkenes, one with a hexyl side chain (150, R = C6H13) and 
another with a phenyl side chain (150, R = Ph), were synthesized to compare the 
potential influence of functional groups of side chains in the coupling reaction. These 
two attempts also failed to yield the desired Sonogashira coupling products. Further, a 
trans-dichloroalkene with a hexyl side chain was synthesized and submitted to the 
Sonogashira coupling reaction with N-Boc propargylamine, which also failed to give 
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the desired coupling products, indicating that stereochemistry of the double bond does 
not present hindrance for the reaction. Sonogashira coupling reactions were also 
attempted between a cis-1,2-dibromoalkene with a hydroxyethyl side chain and various 
alkynes, such as propargyl alcohol and propargyl bromide, but none of these attempts 
gave the Sonogoshira coupling product. On the other hand, it is not surprising that, 
when the Sonogashira coupling reaction was performed between cis-dichloroethene, 
which does not have side chains on the alkene, and N-Boc propargylamine, the 
Sonogashira coupled product was produced in 70% yield, as was reported in the 
literature.59 
 
Scheme 3-2: Reagents and conditions a). Pd(PPh3)4, CuI, Et3N, dry benzene, 45°C, 
overnight. 
 
In a control experiment (Scheme 3-2B), N-Boc-propargylamine 146a alone was 
treated under the same Sonogashira reaction conditions. Surprisingly, the product 
observed in this control reaction had the same Rf with the product observed in the 
previous Sonogashira coupling reaction between dihaloalkenes and N-Boc-
propargylamine (Scheme 3-2A). The product from this control reaction was isolated, 
and its structure characterized by NMR and mass spectroscopy. To our surprise, the 
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product from this control reaction was shown to be the trimer of the N-Boc-
propargylamine 146a. As expected, a dimer of the N-Boc-propargylamine was also 
shown to be present in the reaction mixture, which is a common by-product formed in 
Sonogashira coupling reactions.150  
3.1.2 Homocoupling of terminal alkynes 
Alkyne dimerizarion is a well-known side reaction under Sonogashira reaction 
conditions.150 Similarly, several reports can be found in the literature on the metal 
catalyzed [2+2+2] trimerizarion of alkynes, which have found utility in the rapid 
construction of substituted benzene derivatives. 151  Examples for such type of 
trimerization reactions are shown below (Scheme 3-3).  
 
Scheme 3-3: Metal calayzed [2+2+2] trimerizarion of alkynes 
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As shown in Scheme 3-3a, a molybdenum (0) comlex catalyzed cycloaromatazation of 
a terminal alkyne, ethylpropionate (153), gave a mixture of 1,2,4- and 1,3,5-
carboxyethoxybenzenes (154 and 155) in a 2:1 ratio.152 Yamamoto and co-workers 
reported a cyclotrimerization of 1-perfluoroalkylenynes (156) in the presence of a 
nickel catalyst Ni(PPh3)4, prepared from Ni(cod)2 and PPh3 (Scheme 3-3b).
153 This 
cycloaromatization reaction proceeded in a highly regioselective manner to give 1,2,4-
regioismer (157) together with trace amount of 1,3,5-isomer. In another report a multi 
catalytic system containing Pd(OAc)2, chlorohydroquinone (HQ-Cl) 
molybdovanadophosphate (NPMoV) in the presence of dioxygen was used for the 
cycloaromatization of internal alkynes (Scheme 3-3c).154 An alkyne 158, for example, 
underwent cycloaromatization under these conditions to give a fully substituted 
benezene derivative 159. Self-trimerization and tetramerization of alkynes to form 
branched products under cross-coupling reaction conditions, however, are very rare. To 
the best of our knowledge, there are only three such examples reported in the literature. 
Rossi et al. first reported the formation of dimerized 161 and tetramerized 162 products 
when aliphatic alkynes 160 were treated under Sonogashira conditions in the presence 
of chloroacetone as a reoxidant (Scheme 3-4).155 Two other similar reactions catalyzed 
by palladium (0) or zirconocene in the presence of an oxidant such as p-chloranil or 
dichlorodicyanobenzoquinone were reported.156, 157 
 
Scheme 3-4: Reagents and conditions: Pd(PPh3)4, CuI, benzene, ClCH2COCH3, Et3N. 
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The homo trimerization of terminal alkynes, on the other hand, has not been 
observed to date under the Sonogashira reaction conditions used in our investigations, 
which stimulated us to further explore this reaction for its substrate scope. Prior to 
investigating the substrate scope of this reaction, the roles of reaction components such 
as dihaloalkene, Pd-catalyst, CuI, and a base in the trimerization of alkyne 
wereinvestigated. As a starting point, a control reaction was performed by eliminating 
dihaloalkene from the reaction components, which produced the alkyne trimer, 
indicating that alkenes did not play a role in the trimerization of alkyne. In another set 
of three control reactions, performed in the absence of Pd-catalyst, CuI, or base, no 
trimer product formation was observed (entries 2, 3, and 4, Table 1). While virtually no 
reaction was observed in the absence of CuI, only the homocoupled alkyne dimer was 
isolated in the absence of palladium catalysts. The observations made from these three 
control experiments confirmed the roles of all three components in the trimerization 
reaction.  
 
3.1.3 Optimization of the reaction conditions for the self-trimerization 
of terminal alkynes 
 
The reaction conditions were optimized for the self-trimerization of N-Boc-
propargylamine (Scheme 3-2B). Results are summarized in Table 3-1. Varying in the 
percentage of catalyst, solvent, and base, as well as reaction temperature were shown 
to influence the yield of the trimerized product.  
 
Table 3-1: Optimization of reaction conditions described in Scheme 3-2B 
Entry Reaction 
temperature 
and time 
Solvent Base Catalyst Isolated 
yield 
1 45oC, 15 h Benzene n-butylamine Pd(PPh3)2Cl2  
(5 mol%) 
40 % 
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CuI (5 mol%) 
2 45oC, 15 h Benzene No base Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
n/o 
3 45oC,15 h Benzene n-butylamine CuI (5 mol%) n/o 
4 45oC, 15 h Benzene n-butylamine Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
n/o 
5 45oC, 15 h Benzene n-butylamine Pd(PPh3)2Cl2  
(15 mol%) 
CuI (15 mol%) 
37 % 
6 RT, 15 h Benzene n-butylamine Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
30 % 
7 75 oC, 15 h Benzene n-butylamine Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
n/o 
8 45 oC, 3h THF n-butylamine Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
28 % 
9 45 oC, 15 h MeOH n-butylamine Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
10 % 
10 45 oC, 15 h DMF n-butylamine Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
14 % 
11 45 oC, 15 h 1,4-
Dioxane 
n-butylamine Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
36 % 
12 45 oC, 15 h Benzene DBU Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
20 % 
13 45 oC, 15 h Benzene Hünig's base Pd(PPh3)2Cl2  
(5 mol%) 
CuI (5 mol%) 
10 % 
n/o: not observed 
 
Two palladium catalysts, Pd(PPh3)2Cl2 and Pd(PPh3)4, were shown to give 
similar yields of the trimerized product. The initial conditions (entry 1) with 5 mol% 
of Pd-catalyst and 5 mol% CuI led to the formation of the trimerized product in a yield 
of 40 %. Increasing the catalyst loading to 15 mol% was shown to have very little effect 
on the yield (entry 5). A lower yield was observed when the reaction was performed at 
room temperature instead of 45 °C (entry 6), however, no detectable trimerized product 
was observed by TLC when the reaction was carried out at 75°C (entry 7). Lower yields 
were also observed for reactions performed in polar solvents such as THF, MeOH, 
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DMF, and dioxane (entries 8, 9, 10, and 11) in comparison to those performed in 
benzene. When bases such as DBU and DIPEA, which are characterized by higher 
basicity but lower nucleophilicity compared with butylamine, were used, lower yields 
of product formation were also observed (entries 12 and 13).  
 
3.1.4 Exploring the substrate scope for the self-trimerization of 
terminal alkynes 
 
The substrate scope of the alkyne trimerization reaction was explored with various 
commercially available alkynes (146 a-h) such as propargyl alcohol, N-acetyl-
propargylamine, 3-butyne-1-ol, N-Boc-1-amino-3-butyne, phenyacetylene, and 1-
octyne. The results of these reactions are summarized in Table 3-2. With the exception 
of phenylacetylene (146g) and 1-octyne (146h), trimerized products (152), together 
with the corresponding homodimers (163), were formed from all other alkyne substates. 
Reactions with phenylacetylene (146g) and 1-octyne (146h) did not lead to the 
formation of corresponding trimerized products, possibly due to the absence of a 
heteroatom in these alkyne substrates which might be important for catalyst binding. 
Surprisingly, reactions of alkynes with a -CH2CH2- spacer between acetylene and the 
heteroatom yielded tetramerized products (164 e, f) in addition to the homodimer and 
homotrimer. Considering that trimerized and tetramerized products were only formed 
when alkynes with heteroatoms were used for the reaction, we hypothesized that 
presence of a heteroatom in the alkyne substrate is a requirement for homotrimerization 
and tetramerization.  
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Table 3-2: Homocoupling products of terminal alkynes. Reagents and conditions: a). 
Pd(PPh3)4, CuI, Et3N, dry benzene, 45°C, overnight. 
 
 
Entry Substrate Product yield (%) 
 R = Dimer Trimer Tetramer 
1 CH2NHBoc (a) 10 40 n/o 
2 CH2OH (b) 53 31 n/o 
3 CH2NHAc (c) 20 61 n/o 
4 (CH2)2NHBoc (d) 60 10 10 
5 (CH2)2OH (e) 20 30 23 
6 CH2OCH3 (f)  n/o n/o n/o 
7 Ph (g) 69 n/o n/o 
8 (CH2)4CH3 (h) 40 n/o n/o 
n/o: not observed.  
 
Since the trimerized and tetramerized products are Bergmann cyclization precursors, 
we were curious to see whether these compounds undergo Bergmann cyclization upon 
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heating to produce substituted benzene derivatives. For this purpose, two trimerized 
products of N-Boc-propargylamine and propargyl alcohol were investigated. The 
compounds were individually dissolved in either benzene or methanol and heated under 
reflux for two days. Unfortunately, these attempts did not result in Bergmann 
cyclization. The failure might be due to higher temperature requirements for the 
cyclization to occur. 
 
3.1.5 Characterization of the trimerized alkyne products by NOE and 
HMBC NMR spectroscopy 
 
The structures of the trimerized products were confirmed by NOESY and HMBC NMR 
spectroscopy. Structural assignment of the trimerized product (152b) from propargyl 
alcohol is shown below. Three possible geometric isomers (Figure 3-3) were examined 
against the NOE and HMBC spectra of the isolated product. As the structure of the 
trimer cannot be confirmed by 1H and 13C NMR alone, NOE and 2D NMR spectra were 
used to assign the correct structures of the trimers.  
 
Figure 3-3: Possible structures of trimerized product 152 b. 
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Figure 3-4: 1D NMR spectra of compound 152 b in DMSO-d6. Top: NOE spectrum 
of compound 152 b excited at 3.98 ppm (CH2(9-)); bottom: 
1H NMR spectrum of  
152b. 
 
 
Figure 3-5: HMBC spectrum of compound 152b in DMSO-d6. 
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In a NOE experiment, the presence of a NOE signal (Figure 3-4) between the 
two protons indicated by the arrow in 152b1 (Figure 3-4) excludes 152b2 as the 
product, whereas the cross-peak identified in the HMBC spectrum (Figure 3-5) 
between CH(5) and C(3), but not between CH(5) and C(6), confirms 152b1 as the 
correct structure. 
 
3.1.6 Conclusion  
 
In conclusion, various attempts to synthesize the enedyine compund 38 by the treatment 
of substituted dibromoalkenes with N-Boc-propargylamine under Sonogashira reaction 
conditions were unsuccesful. Sonogashira reactions between various dihaloalkenes and 
alkynes were also unsuccessful in yielding the desired enediyne product. A careful 
structure analysis of the product formed under Sonogashira conditions led to the 
discovery of homo trimerization and tetramerization of terminal alkynes. The newly 
discovered reaction was optimized and further investigated for its substrate scope.    
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3.2 Reactions of terminal alkynes with 
trisubstituted (Z)-bromoalkenyl pinacol 
boronates towards the synthesis of 1,2,4,6-
tetrasubstituted   benzenes 
 
3.2.1 Synthesis of pinacolboronate and bromoalkene 
After many unsuccessful attempts at producing the desired enediynes by Sonogashira 
coupling reactions with dihaloalkenes, focus was switched to another class of alkene 
substrate, bromoalkene boronate 165a (Figure 3-6). 
 
 
Figure 3-6: Bromoboronate alkene designed for sequential Sonogashira and Suzuki 
coupling reactions 
 
 This substrate was designed with the aim of performing sequential Sonogashira 
and Suzuki coupling reactions to synthesize the desired enediyne. The bromoalkene 
boronate 165a was synthesized by the treatment of alkyne 166a with boron tribromide 
to generate the (Z)-2-bromo-1-alkenyldibromoborane 167a, followed by the treatment 
with pinacol in one-pot (Scheme 3-5) with an overall yield of 37%. This type of alkene 
substrate has been shown to be useful in sequential Negishi and other palladium-
catalyzed coupling reactions.158  
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Scheme 3-5: Reagents and conditions: a). BBr3, dry DCM, 0 °C–rt; b). Pinacol, dry 
DCM, rt. 
 
The bromoalkene boronate substrate (165a) was then subjected to Sonogashira 
coupling reaction with N-Boc-propargylamine. Surprisingly, the expected Sonogashira 
coupled product 169 did not form. Careful analysis of the product formed in the reaction 
led to the discovery of a novel reaction between bromoboronate alkene and alkyne, 
producing the tetrasubstituted benzene 168f (Scheme 3-6).  
 
Scheme 3-6: Reagents and conditions: Pd(PPh3)4, CuI, DIPEA, 45°C, 15 h. 
 
 Polysubstituted benzenes are known to be useful synthetic intermediates, and 
can be found in many natural products. A considerable amount of literature is available 
regarding the synthesis of these polysubstituted aromatics. Along with other 
approaches, these substituted aromatic compounds are often generated through 
annulation of smaller building blocks. 159  Among these, the preparation of 
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tetrasubstituted benzenes has been accomplished by various methodologies. 160 , 161 
However, challenges remain towards regiospecific synthesis of aromatics of certain 
substitution patterns. As such, our newly discovered reaction can be applied as a novel 
way of synthesizing tetrasubstituted benzene derivatives in a regioselective manner.  
 
3.2.2 Optimization of the reaction conditions for the aromatization 
reaction 
 
Following the discovery of the novel aromatization reaction, conditions were optimized 
for the reaction between bromoalkenyl boronate with an alkyl side chain (165b) and 
propargyl acohol. The reaction was performed at various temperatures and with the use 
of different catalysts, bases, and solvents. The results are summarized in Table 3-3.  In 
the absence of Pd-catalyst, CuI, or base (entries 2, 3, and 4), the reactions did not 
produce aromatized products, indicating that all three reaction components are required 
for the reaction to produce an aromatic product. Lower yields were observed when 
lower molar percentages of the palladium catalyst were used, and upon changing the 
catalyst from Pd(PPh3)4 to Pd(PPh3)2Cl2 (entries 5 and 6). Decreasing the temperature 
from 45°C to room temperature, or increasing the temperature to 75°C also resulted in 
lower yields (entries 7 and 8). The reaction was also performed in a few solvents such 
as THF, acetonitrile, benzene, methanol, and dioxane. While the use of THF produced 
the aromatized product, other solvents failed to produce any observable amount of 
aromatized product (entries 9 10 11 12 and 13). Substituting the base from 
triethylamine to DIPEA also resulted in lower yields  of the product (entry 14). Use of 
other bases, such as DBU or Cs2CO3, failed to produce any aromatized product. The 
best yield (43%) for the aromatization reaction was obtained under the following 
conditions: 5 mol% Pd(PPh3)4, 20 mol % CuI, DIPEA as base, DMF as solvent, and 
reaction temperature set at 45°C. 
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Table 3-3: Optimization of aromatization conditions 
 
Entry Catalyst CuI 
Mol% 
Base  
(1 equiv.) 
Temper
ature 
Solvent Yield 
(%) 
1 Pd(PPh3)4 (5mol%) 20  DIPEA 45 
oC DMF 43% 
2 ----- 20  DIPEA 45 oC DMF n/o 
3 Pd(PPh3)4 (5mol%) - DIPEA 45 
oC DMF n/o 
4 Pd(PPh3)4 (5mol%) 20  - 45 
oC DMF n/o 
5 Pd(PPh3)2Cl2 
(5mol%) 
20  DIPEA 45 oC DMF 23% 
6 Pd(PPh3)4 (1mol%) 20  DIPEA 45 
oC DMF 35% 
7 Pd(PPh3)4 (5mol%) 20  DIPEA rt 
oC DMF 28% 
8 Pd(PPh3)4 (5mol%) 20  DIPEA 75 
oC DMF 31% 
9 Pd(PPh3)4 (5mol%) 20  DIPEA 45 
oC THF 9% 
10 Pd(PPh3)4 (5mol%) 20  DIPEA 45 
oC CH3CN n/o 
11 Pd(PPh3)4 (5mol%) 20  DIPEA 45 
oC Benzene n/o 
12 Pd(PPh3)4 (5mol%) 20  DIPEA 45 
oC CH3OH n/o 
13 Pd(PPh3)4 (5mol%) 20  DIPEA 45 
oC Dioxane n/o 
14 Pd(PPh3)4 (5mol%) 20  Et3N 45 
oC DMF 11% 
15 Pd(PPh3)4 (5mol%) 20  DBU 45 
oC DMF n/o 
16 Pd(PPh3)4 (5mol%) 20  CS2CO3 45 
oC DMF n/o 
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n/o: not observed 
 
While the reactions described in Table 3-3 are typically rather clean as judged by TLC, 
isolated yields for the aromatization products range from low to moderate, as can be 
seen in Table 3-3. Given the lower than expected yields, the trisubstituted (Z)-
bromoalkenyl-pinacolboronates 165 were suspected to be prone to side reactions under 
the reaction conditions described in entry 1. To verify this, a control reaction was 
performed with compound 165a.  
 
 
Scheme 3-7: Side reaction observed under the conditions of entry 1 in table 3-3 
 
Thus, treatment of (Z)-bromoalkenyl-pinacolboronate 165a alone with Pd(PPh3)4, CuI, 
and Hünig’s base (in the absence of terminal alkynes) was found to lead to the formation 
of alkyne 163e (Scheme 3-7). This side reaction might be one of the factors leading to 
the rather low yield of the aromatized reaction. Conditions that suppress the formation 
of the observed side product may help to improve the yield of the aromatized product.  
 
3.2.3 Exploring the substrate scope for the aromatization reaction 
The substrate scope of this reaction was also explored by treating various bromoalkene 
boronates with different side chains and various terminal alkynes under the optimized 
conditions for aromatization (Entry 1, Table 3-3). Three bromoalkene boronates (165 
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a-c) with different side chains were synthesized using the procedure described 
previously (Scheme 3-5). Purification of the bromoalkene boronate with a phenyl side 
chain (165c) by column chromatography resulted in decomposition of the product. 
Table 3-4: Substrate scope of the aromatization reaction. Reagents and conditions: a). 
Same as entry 1 in Table 3-3. 
 
 
     165       168 Yield % 
a: R = -CH2CH2OH a: R = CH2-CH2-OH, R' = CH2OH 43 
 b: R = CH2-CH2-OH, R' = CH2NHBoc 16 
 c: R = CH2-CH2-OH, R' = CH2NHAc 24 
 d: R = CH2-CH2-OH, R' = Ph n/o 
b: R = -(CH2)5CH3 e: R = CH3-(CH2)5-, R' = CH2OH 37 
 f: R = CH3-(CH2)5-, R' = CH2NHBoc 16 
 g: R = CH3-(CH2)5-, R' = CH2NHAc 39 
 h: R = CH3-(CH2)5-, R' = Ph n/o 
c: R = -Ph i: R= Ph, R' = CH2OH 20 
 j: R = Ph, R' = CH2NHBoc 27 
 k: R = Ph, R' = CH2NHAc 14 
 l: R = Ph, R' = Ph n/o 
n/o: not observed  
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Yields calculated for the aromatization reaction performed by this particular alkene 
(165c) were based on the crude starting material. Structures of the compounds produced 
by the attempted substrates (various bromoalkene boronates and alkynes) are shown in 
Figure 3-7. Aromatization reactions performed with phenylacetylene as the alkyne 
component failed to yield any aromatized product, possibly due to the steric hindrance 
of the phenyl group.  
 
       
Figure 3-7: Products generated in the aromatization reactions with various alkene 
and alkyne substrates 
   
3.2.4 Mechanistic investigations of the aromatization reaction between 
a bromoalkene boronate and an alkyne 
 
The product of an aromatization reaction between a bromoalkene boronate and an 
alkyne contains one alkene and three alkyne units. This reaction can be either a single-
step or multi-step process. In the current work, attempts were made to investigate the 
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mechanistic aspects of this newly discovered reaction. In an attempt to elucidate 
reaction pathways, the aromatization reaction was quenched two hours after the 
reaction commenced. Two intermediates, not found in the products when the reaction 
was allowed to proceed to completion, were isolated. One of the intermediates (170) 
(Figure 3-8) was confirmed by NMR and mass spectrometry to be the Sonogashira 
coupling product 170, while the other intermediate (tentatively assigned as 171 but 
could not be confirmed by spectroscopy) apparently resulted from two rounds of 
coupling of alkene with N-Boc-propargylamine; however, the exact structure of the 
product could not be established at this time. These two intermediates were individually 
subjected to reactions with N-Boc-propargylamine under the same reaction conditions 
used for the aromatization reaction, but neither could produce the aromatized product.  
 
 Based on these observations, we hypothesized that the catalytic cycle of the 
reaction contains these two isolated intermediates but in a form that is co-coordinated 
to either palladium or copper; upon isolation, the intermediates formed in the reaction 
mixture lose their co-ordination with the metal, thus losing the ability to continue the 
catalytic cycle. In another attempt to investigate the reaction pathway, intermediate 170 
was treated with an alkyne dimer; however, no aromatized products were observed to 
form, possibly for the same reasons as explained above. 
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Figure 3-8: Two intermediates isolated in the aromatization reaction  
 
 Since the structure of the second intermediate could not be identified, we 
proposed a mechanism for the aromatization reaction based on the first intermediate. In 
the first step of the proposed mechanism, Sonogashira coupling occurs at the quaternary 
carbon of bromoalkene boronate to give the Sonogashira-coupled product 169. This 
may be followed a [4+2] cyclization with a dimerized diyne to produce the final 
aromatized product 168f (Scheme 3-8).  
 
Scheme 3-8: Proposed mechanism for the aromatization reaction 
 
3.2.5 Conclusion 
In conclusion, bromoalkene pinacoboronate, intended for sequential Sonogashira and 
Suzuki coupling reactions, failed to produce the desired coupling product. The failed 
attempts led to the discovery of a new reaction, where bromoalkene pinacoboronate and 
terminal alkynes reacted to produce tetrasubstituted benzene under Sonogashira 
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conditions. This reaction has the potential to be used for the synthesis of highly 
substituted benzene derivatives. The optimized reaction conditions and substrate scope 
of the aromatization reaction were demonstrated. A few attempts were made to 
understand the reaction pathway of the reaction.   
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3.3 Reactions of BODIPY with cupric nitrate 
BODIPY fluorophores have found increasing applications in various areas such as 
biological and material sciences; as such, synthesis of functionalized BODIPYs is an 
active research topic in the synthetic community (discussed in chapter 2).62 Although 
there are a number of reports in the literature for the synthesis of functionalized 
BODIPYs, the introduction of functional groups to BODIPYs that allow for further 
transformations remains a challenging task. To this end, we have introduced new 
chemical transformations of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene (173) upon treatment with cupric nitrate trihydrate in 
acetonitrile (Scheme 3-9).  
 
 
Scheme 3-9: Transformations of BODIPY with Cu(NO3)23H2O 
3.3.1 Various transformations of BODIPY with Cu(NO3)23H2O 
The outcome of the transformations described in Scheme 3-9 was found to depend on 
the molar equivalents of cupric nitrate trihydrate and the water content in the reaction 
mixture. Variations in these conditions could produce different BODIPYs products 
characterized by a variety of functional groups such as nitro-, nitromethyl-, 
carboxaldehyde, and hydroxymethyl functionalities (174 a-d). Thus, when 4,4-
difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (173) was 
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treated with a half molar equivalent of cupric nitrate trihydrate in wet acetonitrile and 
dichloromethane (containing 0.004% water), 4,4-difluoro-3-nitromethyl-1,5,7,8- 
tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (174a) was isolated in 54% 
yield after column chromatography.  
 
 
Scheme 3-10: Reagents and conditions: a). Cu(NO3)2·3H2O (0.5 eq.), wet CH2Cl2, 
wet MeCN; b). Cu(NO3)2·3H2O (5 eq.), dry CH2Cl2, dry MeCN; c). Ca(NO3)2·4H2O 
(10 eq.), wet CH2Cl2, wet MeCN;  d). Cu(NO3)2·3H2O (5 eq.), wet CH2Cl2, wet 
MeCN. 
 
 Treatment of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene (173) with five molar equivalents of cupric nitrate trihydrate in dry 
acetonitrile and dichloromethane, however, led to the formation of a mixture of 4,4-
difluoro-3-nitro-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (174b) 
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and 4,4-difluoro-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene-3-
carboxyaldehyde (174d) in an approximate 6:1 ratio, as determined by NMR 
spectroscopy. It was further observed that treatment of 4,4-difluoro-1,3,5,7,8 
pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (173) with ten molar 
equivalents of calcium nitrate in the presence of 0.1 molar equivalent of cupric nitrate 
trihydrate in a mixture of acetonitrile and dichloromethane containing 0.02% water led 
to the formation of 4,4-difluoro-3-hydroxymethyl-1,5,7,8-tetramethyl-2,6-diethyl- 4-
bora-3a,4a-diaza-s-indacene (174c) in 50% isolated yield (Scheme 3-10).  
 
3.3.2 Optimization of the reaction conditions for the synthesis of 3-
nitro BODIPY 174b  
 
In order to optimize the yield and to provide mechanistic insights, the reaction for the 
formation of 4,4-difluoro-3-nitro-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-
s-indacene (3-nitro BODIPY, 174b) was carried out under different conditions. Thus 
BODIPY 173 was first treated with varied equivalents of cupric nitrate trihydrate in the 
presence or absence of oxygen. The highest yield (62%) for 3-nitro BODIPY 174b was 
obtained when BODIPY 173 was treated with five molar equivalents of 
Cu(NO3)23H2O in dry ACN/DCM (table 3-5: entry 1). Increasing the molar 
equivalents of cupric nitrate trihydrate from 5 to 10 equivalents lowered the yield to 
50% (table 3-5: entry 2). In an effort to understand the role of solvents in this 
transformation, BODIPY 173 was treated with Cu(NO3)23H2O (10 molar equivalents) 
in dry DMF, THF, DMSO, and acetone (table 3-5: entries 3, 4, 5, and 6). No reaction 
was observed under these conditions. These observations seem to suggest that hydration 
of cupric nitrate plays a role in this transformation. Considering that the donor strengths 
or Lewis basicity of DMF, THF, DMSO, and acetone are greater than those of 
dichloromethane and acetonitrile, it is conceivable that water co-ordinated to the metal 
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center might have been displaced in solvents such as DMF, THF, DMSO, and acetone; 
however, the full extent of this hypothesis is not understood at this time.162 
 
Table 3-5: Optimization of conditions for the synthesis of 3-nitro BODIPY 65b 
 
 metal salts Solvents air 174a 174b 174c 175d Note 
 Cu(NO3)23H2O 
mol. equiv. 
       
1 5  Dry 
DCM/ACN 
Y trace 62% - 11%  
2 10 Dry 
DCM/ACN 
Y trace 50% - 10%  
3 10 Dry DMF Y - - - - n/o 
4 10 Dry THF Y - - - - n/o 
5 10 Dry DMSO Y - - - - n/o 
6 10 Dry Acetone Y - - - - n/o 
7 10 Dry ACN N 9% 12% - 15%  
8 Ca(NO3)24H2O 
12 mol. equiv. 
Dry ACN Y - - - - n/o 
10 AgNO3 
12 mol. equiv. 
Dry ACN Y - - - - n/o 
n/o: not observed 
 
 It was also speculated that oxygen could be involved in the conversion of 
methyl- into the nitro- functional group in this transformation. To verify this, a control 
reaction was performed between BODIPY 173 and cupric nitrate trihydrate in the 
absence of oxygen. Degassing was performed by first freezing a solution of BODIPY 
173 in acetonitrile with liquid nitrogen, and then evacuating the reaction flask. After 
repeating the procedure three times in order to ensure that oxygen was completely 
removed from the reaction flask, Cu(NO3)23H2O was added to the mixture and again 
degassed the reaction mixture for three times. The reaction mixture was then brought 
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to room temperature and stirred for 30 min. As expected, in the absence of oxygen, a 
drastic difference in the yield of 3-nitro BODIPY 174b (12% versus 62% in the 
presence of air) was observed (table 3-5: entry 7), clearly indicating that oxygen is 
involved in the transformation of methyl- into the nitro functional group. Once the 
involvement of oxygen in this reaction was confirmed, the possibility of the reaction 
occurring through radical intermediates was investigated. For this purpose, an excess 
of radical quencher (2,2,6,6-tetramethylpiperidine-1-oxyl, TEMPO) was added to the 
solution prior to the addition of Cu(NO3)23H2O. Virtually no difference was found for 
this transformation, compared with the reaction carried out in the absence of TEMPO. 
It is possible that either the reaction does not go through radical intermediates, or the 
half-life of those radicals is so short that the radicals cannot be quenched by TEMPO 
before the actual transformation occurs. Use of nitrates such as Ca(NO3)2 and AgNO3 
in this reaction, instead of Cu(NO3)23H2O, did not lead to formation of 3-nitro 
BODIPY. Although the mechanism involving the conversion of the methyl group of 
the BODIPY to the nitro group is not clear at this time, the possibility of introducing 
other functional groups with the use of a similar method was explored. Thus, reactions 
were performed with various copper salts such as CuI, CuCl2, Cu(OAc)2, and Cu(SO4)2, 
but none of these reactions resulted in respective functional group transformations, that 
is, iodination, chlorinaton, sulfation, and acylation. Future experiments will be required 
to provide a better understanding of the mechanism of the transformation.  
The introduction of functional groups, such as nitro, nitromethyl, 
carboxaldehyde, and hydroxymethyl, into the BODIPY core with the use of 
Cu(NO3)23H2O can be useful for further transformations, while the obtained modified 
BODIPY compounds can also be used towards the preparation of fluorescent labeling 
agents. One compound, 3-nitro BODIPY 174b, is of particular interest. While the 
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fluorescence of this compound is virtually quenched (Φ = 0.01), upon reduction by 
catalytic hydrogenation (Scheme 3-11), the resulting 3-amino BODIPY 175 becomes 
rather fluorescent (Φ = 0.40). This compound is anticipated to be useful as a fluorescent 
turn-on sensor for reductive environments. 
Scheme 3-11: Reduction of compound 65b to amino BODIPY 
 
3.3.3 Conclusion  
Various functional groups such as 3-nitro, nitromethyl, carbaxaldehyde, and 
hydroxymethyl have been introduced into the BODIPY core under mild conditions with 
the use of a single reagent Cu(NO3)23H2O. Variations in the reaction conditions, such 
as changing the equivalents of Cu(NO3)23H2O and altering water content, resulted in 
the formation of different BODIPYs containing one of the functionalities described 
above. These functionalized BODIPY compounds are useful for conjugating BODIPYs 
to several classes of molecules of interest. While 3-nitro BODIPY 174b is virtually 
non-fluorescent, fluorescence is restored upon reduction of nitro- to amino group, and 
thus this modification has the potential to be useful as a turn-on fluorescence probe for 
the reductive environment.   
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3.4 Microwave-assisted synthesis of BODIPY-
sugar conjugates through Click chemistry and 
assembly of the conjugate into liposomes 
 
In recent years, the fluorescent labeling of glycans has gathered increased popularity in 
applications such as fluorescent imaging of systems involving glycans, and as 
fluorescent substrates for glycan-processing enzymes. The use of fluorescently labeled 
glycans can aid in the study of glycan trafficking and localization, and 
glycosytransferases and glycosidases.163 Research in our laboratory has been focused 
on the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) fluorophore due to its 
practicle properties, such as relatively high photochemical stability, high fluorescent 
quantum yields, and relative independence of fluorescence on pH. The currently 
presented project aimed at conjugating four glycans to modified BODIPY fluorophores.  
 
 
Figure 3-9: Glycans with either an alkyne or azide 
 
These glycans, gifted to us by the Sussex Research Laboratories in Ottawa, include 
glucoside (Glc) 176, N-acetyl-glucosamine glycoside (GlcNAc) 177 and 179, and 
lactoside 178, and have either azido or alkynyl functional groups at the terminal 
position of the PEG spacer covalently β-linked to sugars at the anomeric position 
(Figure 3-9). Since glycan substrates contain either alkyne or azido functional groups 
attached through a spacer, click chemistry was chosen as the method of choice for the 
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conjugation of these sugar molecules to the BODIPY, as click chemistry is a well-
known method in organic synthesis, and is often chosen as a suitable technique for 
conjugation chemistry due to its compatibility with many functional groups and lack of 
byproduct formation.  
 
3.4.1 Synthesis of BODIPY derivatives with alkyne and azido 
functional groups 
 
In order to perform conjugations with carbohydrates using Click chemistry, an azido or 
terminal alkynyl functionality needed to be incorporated into BODIPY. For this 
purpose, alkynyl BODIPY 181 was obtained through the sequential treatment of pyrrole 
69 with acid chloride 180, boron trifluoride diethyl etherate, and triethylamine to give 
the product in 37 % yield (Scheme 3-12A). Acid chloride 180 was prepared through 
the treatment of the corresponding acid with oxalyl chloride in the presence of DMF as 
a catalyst, using dichloromethane as a solvent. The reaction mixture was distilled to 
give acid chloride 180. The azido BODIPY compound 184 was synthesized using a 
two-step process.   
Scheme 3-12: Reagents and conditions: a). i. Dry DCM, reflux, 3h, ii. Et3N, 
BF3OEt2, reflux 3 h. b). NaN3, H2O-DMF, 10 min, 80°C, MW. 
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First, bromo BODIPY 183 was synthesized by the same method used for the synthesis 
of alkynyl BODIPY 181. Next, bromo BODIPY 183 was treated with sodium azide in 
a water-DMF mixture under microwave irradiation for 10 min to produce the azido 
BODIPY 184 in 90% yield (Scheme 3-12B). It is worth noting that while the 
microwave-assisted transformation from bromo BODIPY 183 to azido BODIPY 184 
proceeded smoothly and was completed in five minutes, an attempt at the same 
transformation under conventional heating in DMF in oil-bath and stirring for 3 hrs 
resulted in a much lower yield (<30%).  
 
3.4.2 Synthesis of BODIPY-sugar conjugates through click reaction 
Synthesis of BODIPY sugar conjugates was attempted by using click reaction 
conditions. Alkynyl BODIPY 181 and azido sugar 178 were treated with 2 mol% 
CuSO45H2O and 10 mol% sodium ascorbate in a H2O – t-BuOH mixture at room 
temperature for 2 days. Surprisingly, on the TLC no product spot was observed under 
these conditions. The same reaction mixture was loaded with an additional 10 mol% 
CuSO4 and 20 mol% sodium ascorbate and stirred for another two days under reflux, 
no formation of the product spot was observed either. While it was speculated that the 
solubility of the nonpolar BODIPY in polar solvents might have led to the failure of the 
reaction, the same reaction was performed with 10 mol% CuSO4 and 20 mol% sodium 
ascorbate in DMF to increase the solubility of the BODIPY substrate. Surprisingly, 
however, these attempts also failed to yield the desired product. The reaction was also 
carried out in several other solvents such as MeOH and DMSO, and at elevated 
temperatures up to 160°C with the use of an oil-bath, however, all these attempts failed 
to give the desired click chemistry coupling product. Similarly, all attempts for the click 
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reaction between azido BODIPY 184 and alkynyl sugar 179 failed using the reaction 
conditions described above.  
 Finally, the click reaction was performed under microwave (MW) 
irradiation at 80 °C. The reactions were complete in 15 min to produce four BODIPY-
sugar conjugates 185, 186, 187, and 188 in yields ranging from 30-35 % (Scheme 3-
13). One of the starting materials (sugar, as the limiting reagent) of the reaction mixture 
was fully consumed, but lower isolated yields were observed. It is possible that the 
sugar starting material partially degraded upon microwave heating and reasoned for 
lower yields. To verify this possibility, shortening of microwave exposure time from 
15 to 3 min led to the isolation of click reaction products in much higher yields (70-
80%). All BODIPY-sugar conjugates were purified by C18 reverse-phase FPLC with 
an acetonitrile-water mixture as an eluting solvent.  
 
Scheme 3-13: Synthesis of sugar-BODIPY conjugates 
It was interesting to observe the drastic differences in yield obtained for the click 
reaction between alkynyl (or azido)-BODIPY and azido (or alkynyl) sugar under oil-
bath heating, in contrast to microwave heating. It is possible that owing to the extreme 
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contrast in hydrophobicity/polarity between glycan and BODIPY compounds, the 
reaction between azido and alkynyl functionalities is entropically disfavored. Although 
there have been debates on the existence of “microwave-specific effect”,164, 165 it has 
been suggested in the literature that the presence of an electric field may affect the 
orientation of dipolar molecules, and thus could affect the entropic aspect of certain 
reactions.165, 166 
Although regioselectivity for the click reaction in the presence CuSO4 has been known 
to favor the formation of 1,4-substituted triazoles, since our click reaction was 
performed under MW irradiation, we set out to investigate the regioselectivity outcome 
of the BODIPY-sugar conjugated products by NOESY spectra. As expected, products 
of the click reaction under MW irradiation exhibited selectivity exclusively for  1, 4-
substitution. The confirmation for the 1,4-substitution was obtained through an 
evaluation of NOE signals between the triazole C-H proton and methylene protons in 
the NOESY spectra of the click reaction products of sugar 179 and BODIPY 184 
substrates (Figure 3-10). 
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Figure 3-10: NOESY spectra of click reaction product 
 
3.4.3 Formation of liposomes by the BODIPY-sugar conjugate 
Upon dissolution of conjugate 183 in water, the initially clear solution turned turbid 
over time. This observation led us to speculate that these molecules have the ability to 
form liposomes. Since BODIPY-sugar conjugates are characterized by an amphiphilic 
nature, we hypothesized that the conjugate in the water solution reorganized into 
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ordered structures commonly observed in liposomes. To verify the ability of these 
BODIPY-sugar molecules to form liposomes, a standard protocol for the preparation 
of liposomes from lipids was followed.167  For the purpose of this investigation, a 
BODIPY – β-Glc conjugate 185 was dissolved in chloroform, and the solvent 
evaporated to form a thin layer around the round bottom flask. Preheated water was 
then added to the mixture to break the thin layer into hydrated sheets. The mixture was 
then further mixed by grinding with glass beads. The resulting solution was heated to 
70°C, and then brought to room temperature. Bright field microscopy (Figure 3-11A) 
confirmed the formation of spherical structures. The ability of this conjugate to form a 
bilayer liposome structure is consistent with its overall organization of 
hydrophobicity/polarity, where the presence of both hydrophobic and polar moieties in 
the same molecule in a given conjugate renders the molecule amphiphilic, a property 
that allows for its assembly into bilayers in a manner similar to lipids, as represented in 
Figure 3-11.  
 
Figure 3-11: A cartoon illustrating the bilayer formed by the BODIPY–sugar 
conjugates in aqueous solutions 
 
Interestingly, our attempts to generate liposomes from the other three conjugates under 
the same conditions were unsuccessful, presumably due to differences in the overall 
size and geometry of these conjugates.  
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A 
 
 
  B  
      
Figure 3-12: A. Bright field microscope image of a cluster of liposomes formed from 
BODIPY-conjugate of sugar 185; B. Microscope images of a single liposome recorded 
with a Carl Zeiss Axio Observer. Z1 inverted light/epifluorescence microscope with 
ApoTome.2 optical sectioning. (a) Bright field, (b) green fluorescence (ex. 488 nm, em. 
509 nm), (c) red fluorescence (ex. 587 nm, em. 610 nm), and (d) overlay of the green 
and red fluorescence channels (emission spectra obtained by a specific channel to 
collect around the emission values mentioned above) 
 
Fluorescent microscope images of the obtained liposomes are shown in Figure 3-12. A 
closer look at a single liposome-like structure, depicted in Figure 3-12A, is provided 
in Figure 3-12B. The bright field image (Figure 3-12A) corroborates with the 
fluorescence images of the same “giant” liposome (Figure 3-12 Ba to d), with a 
diameter of ca. 6 μm. Surprisingly, when the preparation of liposomes was excited at 
488 nm, i.e. at the green fluorescence channel, there was no detectable fluorescence 
inside the liposomes at emission wavelength 509 nm, while the solution outside the 
liposomes fluoresced green (Figure 3-12Ba). However, when the liposome preparation 
was excited at 587 nm, i.e. at the red fluorescence channel, a strong red fluorescence 
was observed on the periphery of the liposomes (Figure 3-12Bc). Overlay of the two 
images obtained from the green and red fluorescence channel excitation of liposome 
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exhibited different fluorescence properties inside and outside of the liposome (Figure 
3-12Bd). The red shift of BODIPY emission observed on the periphery of the liposomes 
might be due to the high effective concentration of fluorophore (BODIPY) in the 
liposome bilayer, leading to the formation of BODIPY excimers that emit at longer 
wavelengths, as suggested in the literature.168 
  
3.4.4 Conclusion 
Click reactions between BODIPY and sugars were unsuccessful to give the respective 
conjugates under various conditions when heated in an oil-bath. To our surprise, when 
the reaction was performed in the presence of microwaves at 80°C for 3 min, the 
BODIPY-sugar conjugates were obtained at moderate to high yields. One of the 
BODIPY-sugar conjugate (183) was observed to form liposomes upon rehydration. The 
photophysical properties of these liposomes were characterized by fluorescence 
microscopy. Typically BODIPY emits green fluorescence, however, BODIPY present 
in the liposomes exhibits red fluorescence, most probably due to the higher effective 
concentration of BODIPY that leads to excimer formation. 
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Chapter 4 
Experimental Section 
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4.1 General Experimental Procedures 
All chemicals were purchased from Aldrich or TCI America and used without further 
purification unless stated otherwise. Glycans used for conjugating to the BODIPYs 
were gifts from Sussex Research Laboratory Inc, Ottawa, Canada. Solvents were 
distilled: DMF, iPr2EtN, Et2N and pyridine from CaH2; CH2Cl2 from P2O5; MeOH from 
magnesium methoxide; THF, Benzene and Toluene from Na/benzophenone. Desican 
230–400 mesh silica gel 60 was used for flash column chromatography. Thin layer 
chromatography was performed on Silicycle SiliaPlate F-254 TLC plates using the 
following solvent system: 
A: hexanes 
B: hexane-dichloromethane (70:30, v/v) 
C: hexane-ethylacetate (90:10, v/v) 
D: hexane-ethylacetate (60:40, v/v) 
E: hexane-ethylacetate (50:50, v/v) 
F: dichloromethane 
G: dichloromethane-methanol (94:6, v/v) 
H: dichloromethane-methanol (92:8, v/v) 
I: dichloromethane-methanol (90:10, v/v) 
J: dichloromethane-methanol (88:12, v/v) 
K: dichloromethane-methanol-water (40:10:1, v/v) 
 
 NMR spectra were obtained on a Bruker Avance 300, 400 or 600 MHz 
instrument and are referenced to the residual proton signal of the deuterated solvent for 
1H spectra, and to the carbon multiplet of the deuterated solvent for 13C spectra. 
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Tetramethylsilane was used as an internal standard. Spectroscopic data are reported as 
follows: (multiplicity, number of protons, coupling constant), where s = singlet, d = 
doublet, t = triplet, q = quartet, dd = doublet of doublets, and m = multiplet. Chemical 
shifts are reported in ppm and J values are given in Hz. Low and high resolution mass 
spectra were obtained with Kratos Concept 1S high resolution mass spectrometer using 
electron impact sources interfaced with DART 32 bit acquisition system through a Sun 
Sparcstation 10 and Mach 3 software. 
 
4.2 Detailed Experimental Procedures 
4.2.1 Coupling reaction of N-Boc-propargylamine  
 
 
 
 
163a 152a 
 
To a solution of N-Boc-propargylamine (0.200 g, 1.29 mmol) in dry benzene (6.0 mL) 
were added Pd(PPh3)2Cl2 (18 mg, 2 mol%) and n-butylamine (2 mL). The solution was 
frozen followed by addition of CuI (5 mg, 2 mol%). While frozen, the reaction mixture 
was evacuated and then purged with argon. After this degassing procedure was repeated 
two more times, the mixture was stirred at 45°C for 15 h  in an argon atmosphere. After 
the reaction mixture was evaporated under reduced pressure, the residue was taken up 
with dichloromethane (50 mL) and extracted with saturated aqueous sodium hydrogen 
carbonate (10 mL). The layers were separated and the organic layer was dried (MgSO4) 
and evaporated under reduced pressure. The residue was purified by column 
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chromatography on silica gel. The appropriate fractions, which were eluted with ethyl 
acetate–hexanes (30:70 v/v), were combined and evaporated under reduced pressure to 
give the trimerized product 152a as a white solid (80 mg, 40%). Homo coupling dimer 
163a was also isolated as a white solid (20 mg, 10%).  
 
Dimer: 163a 
Rf = 0.73 (System E).  
M.p. 106–108°C (ethanol). 
δH (CDCl3): 1.46 (18 H, s), 4.00 (4 H, d, J = 4.6), 4.77 (2 H, s, br). 
δC (CDCl3): 28.3, 31.0, 67.3, 74.8, 80.3, 155.1.  
MS (ESI+) found 331.2, C16H24N2NaO4
+ requires 331.16. 
 
Trimer: 152a 
Rf = 0.59 (System E).  
δH (CDCl3): 1.44, 1.45, 1.46 (three singlets integrate 27 H, br), 3.80 (2 H, d, J = 5.5), 
3.86 (4 H, br), 4.89 (1 H, s, br), 5.00 and 5.08 (2 H, br), 5.78 (1 H, s). 
δC (CDCl3): 28.4, 31.3, 44.9, 79.8, 79.9, 80.2, 92.4, 93.9, 114.9, 132.0, 155.4, 155.5. 
MS (ESI+) found 464.2741,C22H38N3O6
+ requires 464.2761 
 
4.2.2 Coupling reaction of propargyl alcohol  
 
 
 
 
163b 152b 
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To a solution of propargyl alcohol (0.100 g, 1.78 mmol) in dry benzene (9.0 mL) were 
added Pd(PPh3)2Cl2 (119 mg, 10 mol%) and n-butylamine (2 mL). The mixture was 
frozen followed by addition of CuI (32 mg, 10 mol%). The mixture was evacuated and 
purged with argon. After this degassing procedure was repeated two more times, the 
mixture was stirred at 45°C overnight in an argon atmosphere. The solvents were 
removed under reduced pressure and the residue was purified by column 
chromatography on silica gel without aqueous work up. The appropriate fractions, 
which were eluted with dichloromethane–methanol (93:7 v/v), were combined and 
evaporated under reduced pressure to give the trimerized product 152b as a light yellow 
oil (30 mg, 31%). Homo coupling product 163b was also obtained as a light yellow 
solid (50 mg, 53%). 
 
Dimer: 163b 
Rf = 0.55 (System H). 
δH (DMSO-d6): 4.17 (s, 4 H), 5.40 (2 H, s, br, ex). 
δC (DMSO-d6): 49.8, 68.4, 80.0.  
HRMS (EI) found 110.03661, C6H6O2 requires 110.03678. 
 
Trimer: 152b 
Rf = 0.38 (System H). 
δH (DMSO-d6): 3.98 (2 H, dd, J = 5.8 and 1.7), 4.25 (2 H, dd, J = 5.9 and 1.7), 4.26 (2 
H, d, J = 5.8), 5.27 (1 H, t, J = 5.9, ex), 5.32 (1 H, t, J = 5.9, ex), 5.36 (1 H, t, J = 5.9, 
ex), 6.00 (1 H, t, J = 1.9). 
δC (DMSO-d6): 49.9, 50.0, 63.7, 81.2, 81.8, 96.2, 97.7, 112.4, 135.5. 
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Mass spectrometric analysis of this trimer was unsuccessful, however, upon 
acetylation, the corresponding triacetyl analogue gave correct mass.  
HR-EI found 292.07806, C15H16O6 requires 292.09469. 
 
4.2.3 Coupling reaction of N-acetyl propargylamine  
 
 
 
163c 152c 
 
To a solution of N-acetyl propargylamine (200 mg, 2.06 mmol) in dry benzene (6 mL) 
were added Pd(PPh3)2Cl2 (71 mg, 5 mol%) and n-butylamine (2 mL). The solution was 
frozen followed by addition of CuI (19 mg, 5 mol%). The mixture was evacuated and 
purged with argon. The degasing procedure was repeated two more times, and the 
mixture was stirred at 45°C overnight in an argon atmosphere. The products were 
evaporated under reduced pressure and the residue was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–methanol (92:8 v/v), were combined and evaporated under reduced 
pressure to give the trimerized product 152c as a light yellow solid (120 mg, 61%). 
Homo coupling dimer product 163c was also isolated as light yellow solid (40 mg, 
20%). 
Dimer: 163c 
Rf = 0.38 (System H).  
δH (DMSO-d6): 1.82 (6 H, s), 3.95 (4 H, d, J = 5.1), 8.35 (2 H, s, br).  
δC (DMSO-d6): 22.7, 28.9, 66.2, 76.8, 169.5. 
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Trimer: 152c 
Rf = 0.28 (System H).  
δH (CDCl3): 2.02 (3 H, s), 2.04 (3 H, s), 2.05 (3 H, s), 3.89 (2 H, d, J = 5.8), 4.16 (2 H, 
dd, J = 5.2 and 1.7), 4.18 (2 H, d, J = 5.2), 5.78 (1 H, s), 6.79 (1 H, s), 7.30 (1 H, s), 
7.44 (1 H, s). 
δC (CDCl3): 22.92, 22.93, 23.1, 30.1, 30.2, 43.6, 80.0, 80.1, 92.2, 93.7, 115.7, 131.8, 
170.7. 
 
4.2.4 Coupling reaction of N-Boc-amino-1-butyne  
 
 
 
 
 
163d 152d 164d 
 
To a solution of N-Boc-amino-1-butyne (100 mg, 0.59 mmol) in dry benzene (3 mL) 
were added Pd(PPh3)2Cl2 (20 mg, 5 mol%) and n-butylamine (0.5 mL). The solution 
was frozen followed by addition of CuI (5.6 mg, 5 mol%). The frozen mixture was 
evacuated and purged with argon. This degassing procedure was repeated two more 
times and the mixture was stirred at 45°C overnight in an argon atmosphere. The 
products were evaporated under reduced pressure and the residue was purified by 
column chromatography on silica gel. The appropriate fractions, which were eluted 
with ethyl acetate–hexanes (40:60 v/v), were combined and evaporated under reduced 
pressure to give the trimerized product 152d as a light yellow solid (10 mg, 10%). 
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Tetramerized 164d and dimer 163d coupling products were also isolated as a light 
yellow solid (15 mg, 10%) and white solid (60 mg, 60%), respectively. 
 
Dimer: 163d 
Rf: 0.68 (System E).  
M.p. 130–132°C (ethanol).  
δH (CDCl3): 1.45 (18 H, s), 2.46 (4 H, t, J = 6.3), 3.27 (4 H, dt, J = 5.5 and 6.2), 4.91 (2 
H, s, br).  
δC (CDCl3): 20.8, 28.4, 39.2, 66.4, 75.1, 79.6, 155.6. 
MS: C18H28N2NaO4 requires 359.2, ESI-MS
+ found 359.2. 
 
Trimer: 152d 
Rf: 0.47 (System E). 
δH (CDCl3): 1.45 (17 H, br), 2.36 (2 H, t, J = 5.8), 2.59 (2 H, t, J = 5.9), 2.62 (2 H, J = 
5.9), 3.31–3.36 (6 H, m), 4.77 (1 H, s, br), 5.00 (1 H, s, br), 5.20 (1 H, s, br), 5.64 (1 H, 
s). 
δC (CDCl3): 21.2, 21.3, 28.4, 37.3, 39.1, 39.5, 79.3, 79.5, 79.9, 80.4, 92.6, 95.6, 115.9, 
131.9, 155.7, 155.8. 
MS: C27H44N3NaO6 requires 528.3, ESI-MS
+ found 528.3. 
 
Tetramer: 164d 
Rf: 0.35 (System E). 
δH (CDCl3): 1.45 (36 H, s, br), 2.59–2.66 (8 H, m), 3.31–3.36 (8 H, m), 4.93, 5.04, 5.23 
(4 H, br, m). 
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δC (CDCl3): 21.2, 21.7, 28.4, 29.7, 35.1, 39.1, 39.4, 40.5, 78.1, 79.4, 80.1, 81.6, 90.7, 
95.5, 110.8, 135.3, 155.7, 155.9.  
MS: C36H56N4NaO8 requires 695.4, ESI-MS
+ found 695.5. 
 
4.2.5 Coupling reaction of 3-butyne-1-ol  
 
 
 
 
 
 
163e 152e 164e 
 
To a solution of 3-butyne-1-ol (100 mg, 1.42 mmol) in dry benzene (6 mL) were added 
Pd(PPh3)2Cl2 (24 mg, 2.5 mol%) and n-butylamine (1.5 mL). The solution was frozen 
followed by addition of CuI (6 mg, 2.2mol%). The mixture was evacuated and purged 
with argon. This degasing procedure was repeated two more times and the mixture was 
stirred at 45°C for 45 min in an argon atmosphere. The products were evaporated under 
reduced pressure and the residue was purified by column chromatography on silica gel. 
The appropriate fractions, which were eluted with dichloromethane–methanol (92:8 
v/v), were combined and evaporated under reduced pressure to give the trimerized 
product 152e as a light yellow oil (30 mg, 30%). Tetramerized 164e and dimer 163e 
coupling products were also isolated as a colorless solid (20 mg, 20%) and light yellow 
oil (23 mg, 23%), respectively. 
 
Dimer: 163e 
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Rf: 0.50 (System H). 
δH (DMSO-d6): 2.40 (4 H, t, J = 6.6), 3.49 (4 H, dt, J = 6.6 and 5.5), 4.89 (2 H, d, J = 
5.5). 
δC (DMSO-d6): 23.4, 59.8, 66.4, 76.6. 
HRMS (EI) found 138.06795, C8H10O2 requires 138.06808. 
 
Trimer: 152e 
Rf: 0.40 (System H). 
δH (CDCl3): 2.46 (2 H, t, J = 5.9), 2.68 (2 H, dt, J = 1.9 and 5.9), 2.70 (2 H, t, J = 5.9), 
3.77 (2 H, t, J = 5.8), 3.79 (2 H, t, J = 5.9), 3.83 (2 H, t, J = 6.0), 5.74 (1 H, s). 
δC (CDCl3): 24.1, 39.9, 60.6, 60.7, 60.9, 80.9, 81.6, 92.3, 94.9, 116.6, 131.7. 
MS (ESI+) found 209.2, C12H17O3
+ requires 209.1. 
 
Tetramer: 164e 
Rf: 0.26 (System H). 
δH (CDCl3): 2.67 (2 H, t, J = 6.0), 2.69 (2 H, t, J = 6.0), 2.73 (2 H, t, J = 5.8), 2.75 (2 
H, t, J = 5.8), 3.78 and 3.79 and 3.80 (three sets of triplets, total 6 H, J = 5.8), 3.87 (2 
H, t, J = 6.0).  
δH (DMSO-d6): overlapping signals with DMSO solvent residuals, 3.48–3.56 (8 H, m), 
4.63 (1 H, t, J = 5.4, ex), 4.84 and 4.85 and 4.87 (three sets of triplets, total 3 H, J = 
5.6, ex). 
δC (DMSO-d6): 23.8, 23.9, 24.3, 38.3, 59.6, 60.0, 60.1, 60.2, 78.1, 79.9, 81.5, 91.3, 95.9, 
99.9, 110.2, 135.5. 
MS (EI) found 276, C16H20O4 requires 276.  
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4.2.6 Coupling reaction of phenyl acetylene  
 
163g 
To a solution of phenylacetylene (100 mg, 0.98 mmol) in dry benzene (5 mL) were 
added Pd(PPh3)2Cl2 (68 mg, 10 mol%) and n-butylamine (1 mL). The solution was 
frozen followed by addition of CuI (18 mg, 10 mol%). The mixture was evacuated and 
purged with argon. The degassing procedure was repeated two more times and the 
mixture was stirred at 45°C for 45 min in an argon atmosphere. The products were 
evaporated under reduced pressure and the residue was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with ethyl 
acetate–hexanes (10:90 v/v), were combined and evaporated under reduced pressure to 
give homodimer coupling product 163g as a white solid (70 mg, 69%).  
Rf: 0.48 (System A).  
M.p. 96–97°C (Ethanol). 
δH (CDCl3): 7.34–7.42 (6 H, m), 7.56–7.59 (4 H, m). 
δC (CDCl3): 74.0, 81.6, 121.8, 128.5, 129.2, 132.5. 
HRMS (EI) found 202.07790, C16H10 requires 202.06825. 
 
4.2.7 Coupling reaction of 1-octyne  
 
163h 
To a solution of 1-octyne (500 mg, 4.54 mmol) in dry benzene (16 mL) were added 
Pd(PPh3)2Cl2 (63 mg, 2 mol%) and n-butylamine (4 mL). The solution was frozen 
followed by addition of CuI (17 mg, 2 mol%). The mixture was evacuated and purged 
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with argon. The degassing procedure was repeated two more times and the mixture and 
then stirred at 45°C for 45 min in an argon atmosphere. The products were evaporated 
under reduced pressure and the residue was purified by column chromatography on 
silica gel. The appropriate fractions, which were eluted with hexanes were combined 
and evaporated under reduced pressure to give homo coupling dimer 163h as a viscous 
colorless oil (200 mg, 40%). 
Rf: 0.59 (System A). 
δH (CDCl3): 0.90 (6 H, t, J = 6.8), 1.27–1.44 (12 H, m), 1.48–1.58 (4 H, m), 2.26 (4 H, 
t, J = 7.0). 
δC (CDCl3): 14.0, 19.2, 22.5, 28.3, 28.5, 31.1, 65.2. 
HRMS (EI) found 218.20336, C16H26 requires 218.20345. 
 
4.2.8 (Z)-3-Bromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-buten-1-ol  
 
165a 
To a cooled (ice–water bath) solution of boron tribromide (8.00 g, 31.9 mmol) in dry 
dichloromethane (20 mL) was added drop-wise a solution of 3-butyn-1-ol (1.50 g, 21.4 
mmol) in dry dichloromethane (20 mL). After the addition was completed the solution 
was brought to room temperature and stirred for 3 h. Upon cooling (ice–water bath), a 
solution of pinacol (3.85 g, 32.6 mmol) and dry triethylamine (5.97 mL, 42.8 mmol) in 
dry dichloromethane (20 mL) was added drop-wise. After the reaction mixture was 
stirred for 12 h at room temperature, the products were extracted with brine solutions 
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(3×20 mL). The organic layer was dried over anhydrous MgSO4 and evaporated under 
reduced pressure to give the crude product, which was purified by column 
chromatography on silica gel (eluted with 0–60% ethyl acetate in hexanes) to give the 
title compound 165a as a colorless oil (2.17 g, 37%). The product contains ca. 14% 
inseparable E-isomer as indicated by NMR spectra. 
Rf (System D): 0.44 
δH (CDCl3): 1.306 and 1.308 (together 12 H), 2.77 (2.3 H, including signals from the 
E-isomer, t, J = 5.8), 3.84 (2 H, dt, J = 1.0 and 5.9), 6.01 (1 H, s).  
δC (CDCl3): 24.8, 48.3, 60.2, 83.8, 140.4.  
δB (CDCl3): 29.2 (Z-isomer), 22.5 (E-isomer). 
Mass (ESI positive) found 299.1, C10H18BBrNaO3
+ requires 299.04. 
 
4.2.9 (Z)-2-Bromo-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-octene  
 
165b 
To a cooled (ice–water bath) solution of boron tribromide (6.82 g, 27.2 mmol) in dry 
dichloromethane (30 mL) was added drop-wise a solution of 1-octyne (3.0 g, 27.2 
mmol) in dry dichloromethane (30 mL). After the addition was completed the solution 
was brought to room temperature and stirred for 3 h. Upon cooling (ice–water bath), a 
solution of pinacol (6.42 g, 54.3 mmol) and dry triethylamine (3.21 mL, 23.0 mmol) in 
dry dichloromethane (20 mL) was added drop-wise. After the reaction mixture was 
stirred for 12 h at room temperature, the products were extracted with brine solutions 
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(3×20 mL). The organic layer was dried over anhydrous MgSO4 and evaporated under 
reduced pressure to give the crude product, which was purified by column 
chromatography on silica gel (eluted with 0–30% of ethyl acetate in hexanes) to give 
the title compound as a colorless oil (2.00 g, 23%). The product contains ca. 8% 
inseparable E-isomer as indicated by the 1H NMR spectrum. 
Rf (System D): 0.71. 
δH (CDCl3): 0.89 (3 H, t, J = 6.9), 1.31 (18 H, m), 1.58 (2 H, m), 2.52 (2 H, t, J = 7.5), 
5.88 (1 H, s).  
δC (CDCl3): 14.0, 22.5, 24.8, 28.0, 28.2, 31.5, 45.3, 83.6, 145.3.  
δB (CDCl3): 29.1. 
 
4.2.10 (Z)-α-Bromo-β-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-styrene  
 
165c 
To a cooled (ice–water bath) solution of boron tribromide (14.7 g, 58.7 mmol) in dry 
dichloromethane (60 mL) was added drop-wise a solution of phenylacetylene (6.0 g, 
58.7 mmol) in dry dichloromethane (60 mL). After the addition was completed the 
solution was brought to room temperature and stirred for 3 h. Upon cooling (ice–water 
bath), a solution of pinacol (6.94 g, 58.7 mmol) and triethylamine (18 mL, 0.13 mol) in 
dry dichloromethane (60 mL) was added drop-wise. After the reaction mixture was 
stirred for 12 h at room temperature, the products were extracted with brine solutions 
(3×50 mL). The organic layer was dried over anhydrous MgSO4 and evaporated under 
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reduced pressure to give the crude product (12.0 g, 66%). The compound tends to 
decompose upon purification by column chromatography on silica gel, and thus was 
used without further purification. 
Rf (System D): 0.77. 
 
4.2.11 (Z)-2-(N-Boc-amino-2-propyne)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)-1-octene 
 
170 
To a solution of (Z)-2-bromo-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-octene 
165b (200 mg, 0.631 mmol) and N-Boc-propargylamine (156 mg, 1.00 mmol) in dry 
DMF (3.0 mL) was added diisopropylethylamine (0.60 mL, 3.44 mmol). The solution 
was frozen in liquid nitrogen followed by addition of Pd(PPh3)4 (91 mg, 0.0788 mmol) 
and CuI (60 mg, 0.316 mmol). After evacuation while the mixture was frozen, the 
reaction mixture was purged with nitrogen. This degassing procedure was repeated two 
more times, and the mixture was then stirred at 45°C for 3 h. The products were 
evaporated under reduced pressure and the residue was purified by column 
chromatography on silica gel (0–40% EtOAc in hexane) to give the mono alkyne 
coupled product 170 as a light yellow oil (46 mg, 0.117 mmol, 18%).  
Rf (system D): 0.72.  
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δH (DMSO-d6): 0.85 (3 H, t, J = 6.8), 1.20 (12 H, s), 1.24  (6 H, m), 1.39 (9 H, s), 1.45 
(2 H, m), 2.13 (2 H, t, J = 7.3), 3.88 (2 H, d, J = 5.6), 5.49 (1 H, s), 7.12 (1 H, t, J = 
5.5).  
δC (DMSO-d6): 14.4, 22.5, 25.0, 27.9, 28.5, 28.6, 31.5, 78.6, 82.5, 83.2, 92.1, 124.7, 
142.4, 155.6. 
Mass (ESI positive) found 414.4, C22H38BNNaO4
+ requires 414.28. 
 
4.2.12 3-[2,6-Bis(N-tert-butyloxyaminomethyl)-4-(2-hydroxyethyl)]phenyl-2-
propyn-N-tert-butyloxyamine  
 
168b 
To a solution of (Z)-3-bromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-buten-
1-ol 165a (400 mg, 1.44 mmol) and N-Boc-propargylamine (786 mg, 5.06 mmol) in 
dry DMF (7.0 mL) was added diisopropylethylamine (1.2 mL, 6.89 mmol). The 
solution was frozen in liquid nitrogen followed by addition of Pd(PPh3)4 (376 mg, 0.326 
mmol, 6 mol% with respect to N-Boc-propargylamine) and CuI (247 mg, 1.30 mmol, 
25 mol% with respect to N-Boc-propargylamine). After evacuation while the mixture 
was frozen, the reaction mixture was purged with nitrogen. This degassing procedure 
was repeated two more times, and the mixture was stirred at 45°C overnight in a 
nitrogen atmosphere. The products were then evaporated under reduced pressure and 
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the residue was purified by column chromatography on silica gel (20–60% EtOAc in 
hexane) to give the aromatized product 168b as a light yellow solid (120 mg, 16%).  
Rf: 0.66 (system G). 
δH (DMSO-d6): 1.41 (s, 27 H), 2.69 (2 H, d, J = 6.9), 3.56 (2 H, d, J = 6.9), 4.02 (2 H, 
d, J = 5.5), 4.21 (4 H, 5.6), 6.97 (2 H, s), 7.30 (2 H, t, J = 5.9, ex), 7.40 (1 H, t, J = 5.5, 
ex). 
δC (DMSO-d6): 28.6, 28.7, 31.1, 39.8, 42.6, 62.4, 77.3, 78.3, 78.7, 97.8, 116.9, 125.3, 
139.6, 141.9, 155.9, 156.2.  
MS (ESI+) found 556.2, C28H43N3NaO7
+ requires 556.3. 
 
4.2.13 3-(2,6-Dihydroxymethyl-4-hexyl)prop-2-yn-1-ol 
 
168e 
To a solution of (Z)-2-bromo-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-octene 
165b (150 mg, 0.475 mmol) and propargyl alcohol (93 mg, 1.66 mmol) in dry DMF 
(3.0 mL) was added diisopropylethylamine (0.20 mL, 1.15 mmol). The solution was 
frozen in liquid nitrogen followed by addition of Pd(PPh3)4 (100 mg, 0.0865 mmol, 5 
mol% with respect to propargyl alcohol) and CuI (60 mg, 20 mol%). After evacuation 
while the mixture was frozen, the reaction mixture was purged with nitrogen. This 
degassing procedure was repeated two more times, and the mixture was then stirred at 
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45°C overnight in a nitrogen atmosphere. The products were evaporated under reduced 
pressure and the residue was purified by column chromatography on silica gel (0–6% 
MeOH in dichloromethane) to give the aromatized product 168e as a light yellow solid 
(57 mg, 43%).  
Rf: 0.57 (system I).  
HR-MS (MALDI-TOF positive) found 299.1604, C17H24NaO3
+ requires 299.16231. δH 
(DMSO-d6): 0.86 (3 H, t, J = 6.4), 1.29 (6 H, m, br), 1.56 (2 H, m), 2.60 (2 H, t, J = 
7.6), 4.34 (2 H, d, J = 5.9), 4.60 (4 H, d, J = 5.4), 5.19 (2 H, t, J = 5.5, OH), 5.32 (1 H, 
t, J = 5.9, OH), 7.21 (2 H, s).  
δC (DMSO-d6): 14.4, 22.5, 28.8, 31.3, 31.6, 36.0, 50.1, 61.7, 79.0, 99.1, 114.6, 124.5, 
142.7, 144.2. 
 
4.2.14 3-[2,6-Bis(N-acetamidomethyl)-4-phenyl]phenyl-2-propyn-N-acetylamine  
 
168k 
To a solution of crude (Z)-α-bromo-β-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
styrene 165c (400 mg, 1.29 mmol) and N-acetylpropargylamine (445 mg, 4.59 mmol) 
in dry DMF (6.0 mL) was added diisopropylethylamine (0.75 mL, 4.31 mmol). The 
solution was frozen followed by addition of Pd(PPh3)4 (224 mg, 0.194 mmol, 4 mol% 
with respect to N-acetylproporgylamine) and CuI (147 mg, 0.772 mmol, 17 mol% with 
respect to N-acetylproporgylamine). After evacuation while frozen, the reaction 
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mixture was purged with nitrogen. This degassing procedure was repeated two more 
times, and the mixture was then stirred at 45°C overnight in a nitrogen atmosphere. The 
products were evaporated under reduced pressure and the residue was purified by 
column chromatography on silica gel (0–12% MeOH in dichloromethane) to give the 
aromatized product 168k as a pale yellow solid (70 mg, 14% based on crude alkene). 
M.p. 169°C (decomposed) (dichloromethane–hexane).  
Rf: 0.61 (system I).  
δH (DMSO-d6): 1.89 (3 H, s), 1.92 (6 H, s), 4.19 (2 H, d, J = 5.13), 4.43 (4 H, d, J = 
5.5), 7.38 – 7.52 (5 H, m), 7.61 (2 H, d, J = 7.6), 8.35 (2 H, t, J = 5.4, NH), 5.43 (1 H, 
t, J = 5.0, NH). 
δC (DMSO-d6): 22.9, 23.0, 29.7, 41.6, 77.3, 98.4, 119.3, 124.2, 127.1, 128.3, 129.6, 
139.97, 140.00, 142.3, 169.8, 169.9. 
HR-MS (MALDI-TOF positive) found 414.1741; C23H25N3NaO3
+ requires 414.17881.  
 
4.2.15 3-(2,6-Dihydroxymethyl-4-phenyl)-2-propyn-1-ol  
 
168i 
To a solution of crude (Z)-α-bromo-β-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
styrene 165c (2.00 g, 6.47 mmol) and propargyl alcohol (2.00 g, 33.7 mmol) in dry 
DMF (30.0 mL) was added diisopropylethylamine (11.3 mL, 64.9 mmol). The solution 
was frozen followed by addition of Pd(PPh3)4 (400 mg, 0.346 mmol, 1 mol% with 
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respect to propargyl alcohol) and CuI (258 mg, 1.36 mmol, 4 mol% with respect to 
propargyl alcohol). After evacuation while frozen, the reaction mixture was purged 
with nitrogen. This degassing procedure was repeated two more times, and the mixture 
was then stirred at 45°C overnight in a nitrogen atmosphere. The products were 
evaporated under reduced pressure and the residue was purified by column 
chromatography on silica gel (0–10% MeOH in dichloromethane) to give the 
aromatized product 168i as a light yellow solid (350 mg, 20% based on crude alkene).  
Rf: 0.57 (system I). 
M.p. 181–184°C (ethanol). Found in material recrystallized from ethanol: C, 76.34%; 
H, 5.80%. C17H16O3 requires C, 76.10%; H, 6.01%. 
δH (DMSO-d6): 4.39 (2 H, d, J = 5.6), 4.69 (4 H, d, J = 5.6), 5.34 (2 H, t, J = 5.6, ex), 
5.39 (1 H, t, J = 5.6, ex), 7.38 (1 H, t, J = 7.3), 7.50 (2 H, t, J = 7.5), 7.66 and 7.68 
(together 4 H).  
δC (DMSO-d6): 50.1, 61.7, 78.7, 100.7, 116.4, 122.8, 127.0, 128.2, 129.5, 139.9, 140.5, 
145.0. 
 
4.2.16 3-[2,6-Bis(N-tert-butyloxyaminomethyl)-4-phenyl]phenyl-2-propyn-N-tert- 
butyloxyamine  
 
 
168j 
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To a solution of crude (Z)-α-bromo-β-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)styrene 165c (400 mg, 1.29 mmol) and N-Boc-propargylamine (607 mg, 3.91 mmol) 
in dry DMF (6.0 mL) was added diisopropylethylamine (1.3 mL, 7.46 mmol). The 
solution was frozen followed by addition of Pd(PPh3)4 (224 mg, 0.194 mmol, 5 mol% 
with respect to N-Boc-propargylamine) and CuI (147 mg, 0.774 mmol, 20 mol%). After 
evacuation while frozen, the reaction mixture was purged with nitrogen. This degassing 
procedure was repeated two more times, and the mixture was then stirred at 45°C 
overnight in a nitrogen atmosphere. The products were evaporated under reduced 
pressure and the residue was purified by column chromatography on silica gel (0–60% 
EtOAc in hexane) to give the aromatized product 168j as a colorless solid (198 mg, 
27% based on crude alkene).  
Rf: 0.57 (system D).  
M.p. 114–116°C (dichloromethane–hexane). Found in material recrystallized from 
dichloromethane–hexane: C, 67.77%; H, 7.66%; N, 7.26%. C32H43O6 requires C, 
67.94%; H, 7.66%; N, 7.43%.  
δH (DMSO-d6): 1.42 and 1.43 (together 27 H), 4.07 (2 H, d, J = 5.3), 4.30 (4 H, d, J = 
5.6), 7.41–7.58 (10 H, m). 
δC (DMSO-d6): 28.64, 28.69, 42.7, 77.1, 78.4, 78.8, 99.2, 118.5, 123.3, 126.9, 128.3, 
129.6, 139.8, 140.4, 142.7, 155.9, 156.3. 
HR-MS (MALDI-TOF positive) found 604.2734; C32H43KN3O6
+ requires 604.27834.  
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4.2.17 3-(2,6-Dihydroxymethyl-4-(2-hydroxyethyl))prop-2-yn-1-ol  
 
168a 
To a solution of (Z)-3-bromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-buten-
1-ol 165a (400 mg, 1.44 mmol) and propargyl alcohol (391 mg, 6.97 mmol) in dry 
DMF (7.0 mL) was added diisopropylethylamine (2.0 mL, 11.5 mmol). The solution 
was frozen followed by addition of Pd(PPh3)4 (376 mg, 0.326 mmol, 5 mol% with 
respect to propargyl alcohol) and CuI (247 mg, 1.30 mmol, 19 mol% with respect to 
propargyl alcohol). After evacuation while frozen, the reaction mixture was purged 
with nitrogen. This degassing procedure was repeated two more times, and the mixture 
was then stirred at 45°C overnight in a nitrogen atmosphere. The products were 
evaporated under reduced pressure and the residue was purified by column 
chromatography on silica gel (0–10% MeOH in dichloromethane) to give the 
aromatized product 168a as a light yellow solid (126 mg, 37%).  
Rf: 0.33 (system J).  
δH (DMSO-d6): 2.74 (2 H, t, J = 7.0), 3.61 (2 H, dt, J = 5.2 and 7.0, ex), 4.34 (2 H, d, J 
= 5.8), 4.59 (4 H, d, J = 5.3), 4.66 (1 H, t, J = 5.2, ex), 5.20 (2 H, t, J = 5.4, ex), 5.32 (1 
H, t, J = 5.4, ex), 7.24 (2 H, s). 
 δC (DMSO-d6): 49.5, 50.1, 61.6, 62.5, 79.0, 99.2, 114.8, 125.2, 139.9, 144.1. 
HR-MS (MALDI-TOF positive) found 259.0914; C13H16NaO4
+ requires 259.09408.  
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4.2.18 3-[2,6-Bis(N-acetamidomethyl)-4-phenyl]phenyl-2-propyn-N-acetylamine  
 
168c 
To a solution of (Z)-3-bromo-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-buten-
1-ol 165a (100 mg, 0.36 mmol) and N-acetylpropargylamine (141 mg, 1.45 mmol) in 
dry DMF (3.0 mL) was added diisopropylethylamine (0.2 mL). The solution was frozen 
followed by addition of Pd(PPh3)4 (83 mg, 0.0719 mmol, 5 mol% with respect to N-
acetylpropargylamine) and CuI (55 mg, 0.289 mmol, 20 mol% with respect to N-
acetylproparagylamine). After evacuation under vacuum, the reaction mixture was 
purged with nitrogen. This degassing procedure was repeated two more times, and the 
mixture was then stirred at 45°C overnight in a nitrogen atmosphere. The products were 
evaporated under reduced pressure and the residue was purified by column 
chromatography on silica gel (0–12% MeOH in dichloromethane) to give the 
aromatized product 168c as a light yellow solid (50 mg, 39%).  
Rf: 0.25 (system J).  
HR-MS (MALDI-TOF positive) found 382.1736; C19H25N3NaO4
+ requires 382.17373.  
δH (DMSO-d6): 1.87 (3 H, s), 1.90 (6 H, s), 2.70 (2 H, t, J = 6.9), 3.57 (2 H, t, J = 6.9), 
4.14 (2 H, d, J = 5.2), 4.33 (4 H, d, J = 5.6), 7.01 (2 H, s), 8.26 (2 H, t, J = 5.8), 8.39 (1 
H, t, J = 5.1). 
 δC (DMSO-d6): 22.82, 22.87, 22.99, 29.6, 39.6, 41.4, 62.4, 77.5, 97.0, 117.7, 126.4, 
140.0, 141.5, 169.69, 169.73. 
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4.2.19 3-[2,6-Bis(N-tert-butyloxyaminomethyl)-4-hexyl]phenyl-2-propyn-N-tert-
butyloxyamine  
 
168f 
To a solution of (Z)-2-bromo-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-octene 
165b (0.500 g, 1.58 mmol) and N-Boc-propargylamine (0.860 g, 5.54 mmol) in dry 
DMF (6.0 mL) was added diisopropylethylamine (0.96 mL, 5.51 mol). The solution 
was frozen followed by addition of Pd(PPh3)4 (320 mg, 0.277 mmol, 5 mol% with 
respect to N-Boc-propargylamine) and CuI (210 mg, 1.10 mmol, 20 mol% with respect 
to N-Boc-propargylamine). After evacuation while frozen, the reaction mixture was 
purged with nitrogen. This degassing procedure was repeated two more times, and the 
mixture was then stirred at 45°C overnight in a nitrogen atmosphere. The products were 
evaporated under reduced pressure and the residue was purified by column 
chromatography on silica gel (10–60%, EtOAc–hexane) to give the aromatized product 
168f as a light yellow wax (142 mg, 16%). 
Rf: 0.66 (system D). The product contains a contaminant that is inseparable by column 
chromatography as indicated by NMR spectra. 
δH (DMSO-d6) contains the following signals: 0.85 (3 H, t, J = 6.3), 4.01 (2 H, d, J = 
5.4), 4.20 (4 H, d, J = 5.4), 6.94 (2 H, s), 7.29 (2 H, t, J = 6.3), 7.39 (1 H, br). 
HR-MS (MALDI-TOF positive) found 596.3688; C32H51N3NaO6
+ requires 596.36756. 
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4.2.20 3-[2,6-Bis(N-acetamidomethyl)-4-hexyl]phenyl-2-propyn-N-acetylamine  
 
168g 
To a solution of (Z)-2-bromo-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-octene 
165b (130 mg, 0.410 mmol) and N-acetylpropargylamine (140 mg, 1.44 mmol) in dry 
DMF (3.0 mL) was added diisopropylethylamine (0.2 mL, 1.15 mmol). The solution 
was frozen followed by addition of Pd(PPh3)4 (83 mg, 0.072 mmol, 5 mol% with 
respect to N-acetylpropargylamine) and CuI (54 mg, 0.28 mmol, 20 mol% with respect 
to N-acetylpropargylamine). After evacuation while frozen, the reaction mixture was 
purged with nitrogen. This degassing procedure was repeated two more times, and the 
mixture was then stirred at 45°C overnight in a nitrogen atmosphere. The products were 
evaporated under reduced pressure and the residue was purified by column 
chromatography on silica gel (0–8% MeOH in dichloromethane) to give the aromatized 
product 168g as a light yellow solid (40 mg, 24%).  
Rf: 0.56 (system I).  
δH (DMSO-d6): 0.86 (3 H, t, J = 6.5), 1.28 (6 H, m), 1.52 (2 H, m), 1.87 (3 H, s), 1.90 
(6 H, s), 2.54 (2 H, t, J = 6.9), 4.14 (2 H, d, J = 5.1), 4.33 (4 H, d, J = 5.6), 6.98 (2 H, 
s), 8.25 (2 H, t, J = 5.5), 8.38 (1 H, t, J = 5.1).  
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δC (DMSO-d6): 14.4, 22.5, 22.9, 23.0, 28.8, 29.6, 31.2, 31.6, 35.7, 41.5, 77.6, 96.8, 
117.5, 125.8, 141.5, 142.8, 169.7. 
HR-MS (MALDI-TOF positive) found 422.2424; C23H33N3NaO3
+ requires 422.24196. 
 
4.2.21 4,4-Difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene 
 
173 
A solution of distilled acetyl chloride (0.405 mL, 5.68 mmol) in dry dichloromethane 
(20 mL) was added drop-wise to a stirred degassed solution of 3-ethyl-2,4-
dimethylpyrrole (2.20 mL, 16.23 mmol) in dry dichloromethane (10 mL). After the 
mixture was heated under reflux for 3 h, the solvents were evaporated under reduced 
pressure. The residue was co-evaporated with dry toluene (3×20 mL) and then re-
dissolved in dry dichloromethane (30.0 mL), followed by addition of dry triethylamine 
(2.26 mL, 16.23 mmol). After 15 min boron trifluoride diethyl etherate (2.03 mL, 16.23 
mmol) was added and the mixture was stirred under reflux for 3 h. Upon cooling to 
room temperature, the products were extracted successively with water (30 mL) and 
brine (3×30 mL). The organic layer was separated, dried (MgSO4) and evaporated 
under reduced pressure. The residue was purified by column chromatography on silica 
gel. The appropriate fractions, which were eluted with dichloromethane–hexane (50:50 
v/v), were combined and evaporated under reduced pressure to give the title compound 
as an orange solid (0.78 g, 30%). 
Rf (System F): 0.90 
δH (CDCl3): 1.06 (6 H, t, J = 7.5), 2.34 (6 H, s), 2.42 (4 H, q, J = 7.5), 2.52 (6 H, 
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s), 2.61 (3 H, s). 
δC (CDCl3): 12.4, 14.4, 14.9, 16.9, 17.1, 131.6, 132.3, 136.3, 139.7, 151.8 
δB (CDCl3): 0.66 (t, J = 33) 
δF (CDCl3): -146.0 (q, J = 33) 
HR-FAB found [M+H]+ =318.19648, C18H25BF2N2 requires 318.20788 
 
4.2.22 4,4-Difluoro-3-nitromethyl-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene  
 
174a 
To a solution of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene 173 (100 mg, 0.31 mmol) in dichloromethane (20 mL, dichloromethane was 
first dried by heating in the presence of phosphorus pentoxide and distilled, and then 
0.004 % water (v/v) was added), a solution of cupric nitrate trihydrate in acetonitrile 
(0.41 M, 0.38 mL, 0.5 mol. equiv., acetonitrile was first dried by heating in the presence 
of calcium hydride and distilled, and then 0.004 % water (v/v) was added) was added. 
After the mixture was stirred for 3 h, the products were evaporated under reduced 
pressure. The residue was re-dissolved in dichloromethane (20 mL) and extracted with 
water (3×15 mL). The organic layer was separated, dried (MgSO4) and evaporated 
under reduced pressure. The residue was purified by column chromatography on silica 
gel. The appropriate fractions, which were eluted with dichloromethane–hexane (50:50 
v/v), were combined and evaporated under reduced pressure to give the title compound 
as a red solid (61 mg, 54%). 
Rf: 0.87 (system F).  
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M.p. 196–200°C (dichloromethane–hexanes). 
δH (CDCl3): 1.07 (3 H, t, J = 7.6), 1.10 (3 H, t, J = 7.6), 2.39 (3 H, s), 2.40 (3 H, s), 2.43 
(2 H, q, J = 7.6), 2.48 (2 H, q, J = 7.6), 2.55 (3 H, s), 2.70 (3 H, s), 5.72 (2 H, s). 
δC (CDCl3): 13.0, 14.1, 14.5,14.7, 14.9, 17.1, 17.2, 17.3, 69.4, 131.8, 133.6, 133.9, 
134.6, 135.6, 140.9, 142.2, 159.9.  
δB (CDCl3): 0.47 (t, J = 33.3).  
δF (CDCl3): -143.6 (q, J = 33.3).  
HRMS (EI) found 363.19288, C18H24BF2N3O2 requires 363.19296. 
 
4.2.23 4,4-Difluoro-3-nitro-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene 
 
174b 
To a solution of 4,4-methyl-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene 173 (100 mg, 0.31 mmol) in dry dichloromethane (20 mL), a solution of 
cupric nitrate trihydrate (380 mg, 5 mol. equiv.) in dry acetonitrile (10 mL) was added. 
After the mixture was stirred for 5 min, the products were evaporated under reduced 
pressure. The residue was re-dissolved in dichloromethane (30 mL) and extracted with 
water (3×20 mL). The organic layer was separated, dried (MgSO4) and evaporated 
under reduced pressure. The residue was purified by column chromatography on silica 
gel. The appropriate fractions, which were eluted with dichloromethane–hexane (70:30 
v/v), were combined and evaporated under reduced pressure to give the title compound 
as a red solid (42 mg, 38%).  
Rf: 0.42 (System F). 
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M.p. 212–216°C (dichloromethane–hexanes). 
δH (CDCl3): 1.09 (3 H, t, J = 7.5), 1.16 (3 H, t, J = 7.5), 2.37 (3 H, s), 2.41 (3 H, s), 2.46 
(2 H, q, J = 7.5), 2.64 (3 H, s), 2.72 (2 H, q, J = 7.5), 2.73 (3 H, s).  
δC (CDCl3): 13.4, 13.7, 14.1, 14.2, 14.9, 17.1, 17.9, 18.3, 130.0, 130.2, 130.4, 137.6, 
138.8, 141.5, 142.7, 144.3, 166.8.  
δB (CDCl3): 0.30 (t, J = 28.2).  
δF (CDCl3): -144.6 (q, J = 29.2).  
HRMS (EI) found 349.17713, C17H22BF2N3O2 requires 349.17731. 
It is noted that this reaction gave a mixture of 4,4-difluoro-3-nitro-1,5,7,8-tetramethyl-
2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 174b and 4,4-difluoro-1,5,7,8-tetramethyl-
2,6-diethyl-4-bora-3a,4a-diaza-s-indacene-3-carboxyaldehyde 174d (with a total mass 
of 78 mg) in a ratio of 6.3:1 as determined by 1H NMR. Therefore, the overall yield of 
the title compound is 62%. In addition to the pure 4,4-difluoro-3-nitro-1,5,7,8-
tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 174b (42 mg), separation of the 
rest of product 174b from contaminating aldehyde 174d was rather difficult. 
 
4.2.24 4,4-Difluoro-3-hydroxymethyl-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-
3a,4a-diaza-s-indacene  
 
174c 
To a solution of 4,4-difluoro-1,3,5,7,8-pentamethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene 173 (50 mg, 0.16 mmol) in dichloromethane (8 mL, dichloromethane was first 
dried by heating in the presence of phosphorus pentoxide and distilled, and then 0.02 
% water (v/v) was added), a solution of cupric nitrate trihydrate (4 mg, 0.1 mol. equiv.) 
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and calcium nitrate tetrahydrate (371 mg, 10 mol. equiv.) in acetonitrile (17 mL, 
acetonitrile was first dried by heating in the presence of calcium hydride and distilled, 
and then 0.02 % water (v/v) was added) was added. After the mixture was stirred for 
24 h, the products were concentrated under reduced pressure and the residue was re-
dissolved in dichloromethane (15 mL) and washed with water (3×10 mL). The organic 
layer was separated, dried  (MgSO4)  and  evaporated  under  reduced  pressure.  The 
residue was  purified by column chromatography on silica gel. The appropriate 
fractions, which were eluted with dichloromethane, were combined and evaporated 
under reduced pressure to give the title compound as a red solid (26 mg, 50%).  
Rf: 0.32 (System F).  
M.p. 177–179°C (dichloromethane– hexanes). 
δH (CDCl3): 1.08 (3 H, t, J = 7.5), 1.12 (3 H, t, J = 7.4), 2.38 (6 H, s), 2.44 (2 H, q, J = 
7.5), 2.52 (2 H, q, J = 7.4), 2.54 (3 H, s), 2.67 (3 H, s), 4.76 (2 H, s).  
δC (CDCl3):12.7, 14.2, 14.6, 14.7, 15.8, 17.0, 17.1, 17.2, 55.06, 131.6, 132.1, 133.1, 
134.0, 135.5, 138.9, 141.7, 149.2, 155.8.  
δB (CDCl3): 0.70 (t, J = 34.5). 
δF (CDCl3): -142.7 (q, J = 34.2). 
HRMS (EI) found 334.20272, C18H25BF2N2O requires 334.20280. 
 
4.2.25 4,4-Difluoro-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-
indacene-3-carboxyaldehyde  
 
174d 
To a solution of 4,4-difluoro-3-nitromethyl-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-
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3a,4a-diaza-s-indacene 173 (50 mg, 0.14 mmol) in dichloromethane (10 mL, 
dichloromethane was first dried by heating in the presence of phosphorus pentoxide 
and distilled, and then 0.004 % water (v/v) was added), a solution of cupric nitrate 
trihydrate (172 mg, 5 mol. equiv.) in acetonitrile (5 mL, acetonitrile was first dried by 
heating in the presence of calcium hydride and distilled, and then 0.004 % water (v/v) 
was added) was added. After the mixture was stirred for 3 h, the products were 
evaporated under reduced pressure. The residue was re-dissolved in dichloromethane 
(15 mL) and extracted with water (3×10 mL). The organic layer was separated, dried 
(MgSO4) and evaporated under reduced pressure. The residue was purified by column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane–hexane (70:30 v/v), were combined and evaporated under reduced 
pressure to give the title compound as a red solid (19 mg, 42%).  
Rf: 0.45 (System F). 
M.p. 215–219°C (dichloromethane–hexanes). 
δH (CDCl3): 1.09 (3 H, t, J = 7.6), 1.12 (3 H, t, J = 7.5), 2.36 (3 H, s), 2.42 (3 H, s), 2.47 
(2 H, q, J = 7.6), 2.63 (3 H, s), 2.73 (3 H, s), 2.84 (2 H, q, J = 7.5), 10.37 (1 H, s). 
δC (CDCl3): 13.1, 13.5, 14.3, 14.6, 14.9, 17.2, 17.6, 17.8, 132.0, 133.3, 136.4, 136.9, 
137.4, 138.9, 141.9, 142.0, 163.9, 186.0. 
δB (CDCl3): 0.62 (t, J = 33.1).  
δF (CDCl3): -138.1 (q, J = δ33.0). 
HRMS (EI) found 332.18780, C18H23BF2N2O requires 332.187150. 
 
4.2.26 4,4-Dimethyl-3-amino-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-
s-indacene  
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175 
To a solution of 4,4-difluoro-3-nitro-1,5,7,8-tetramethyl-2,6-diethyl-4-bora-3a,4a-
diaza-s-indacene 174b (57 mg, 0.17mmol) in MeOH-EtOAc (10 mL, 9:1 v/v), 
palladium on activated charcoal (10% loading, 6 mg) was added and the mixture was 
stirred in a hydrogen atmosphere (1 atm) for 2 h at room temperature. The resulting 
mixture was filtered through a bed of celite and the filtrate was concentrated under 
reduced pressure. The crude residue was purified by flash chromatography on silica 
gel. The appropriate fractions, which were eluted with dichloromethane, were 
combined and evaporated under reduced pressure to afford the title compound (43 mg, 
87%) as an orange solid.  
M.p. 239-243°C (dichloromethane–hexanes).  
δH (DMSO-d6): 0.97 and 0.98 (6 H, two triplets, J = 7.5), 2.23 (3 H, s), 2.26 (3 H, s), 
2.27 (3 H, s), 2.33 (2 H, q, J = 7.5), 2.41 (2 H, q, J = 7.5), 2.45 (3 H, s), 7.32 (2 H, s, 
br).  
δC (DMSO-d6): 11.7, 13.4, 14.5, 14.7, 15.6, 15.9, 16.1, 17.1, 125.3, 126.1, 126.9, 127.0, 
128.1, 130.1, 136.0, 140.9, 158.6.  
δB (DMSO-d6): 0.78 (br).  
δF (DMSO-d6): -144.9 (br).  
HRMS (EI) found 319.20310, C17H24BF2N3 requires 319.20313. 
 
4.2.27 4,4-Difluoro-4-bora-1,3,5,7-tetramethyl-2,6-diethyl-8-(hex-5-ynyl)-3a,4a-
diaza-s-indacene 
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181 
A solution of hex-5-ynoyl chloride 180 (84 μL, 0.68 mmol) in dry dichloromethane 
(3.0 mL) was added drop-wise to a stirred solution of 3-ethyl-2-4-dimethyl pyrrole 
(0.22 mL, 1.63 mmol) in dry dichloromethane (6 mL). After the mixture was heated 
under reflux for 4 h, the reaction mixture was cooled to room temperature followed by 
addition of dry triethylamine (1.8 mL, 12.9 mmol). After the mixture was stirred for 30 
min under reflux, boron trifluoride diethyl etherate (1.6 mL, 13.0 mmol) was added and 
the reaction mixture was stirred for 4 h under reflux. Upon cooling to room temperature, 
the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate 
solution (20 mL) and extracted with dichloromethane (3×30 mL). The combined 
organic layers were dried (MgSO4) and evaporated under reduced pressure. The residue 
was purified by column chromatography on silica gel. The appropriate fractions, which 
were eluted by ethyl acetate–hexane (20:80, v/v), were combined and evaporated under 
reduced pressure to give the title compound as a red solid (83 mg, 33%).  
Rf: 0.45 (System C). 
δH (CDCl3): 1.07 (6 H, t, J = 7.5), 1.83–1.91 (2 H, m), 2.07 (1 H, t, J = 2.7), 2.38 (6 H, 
s), 2.39–2.45 (6 H, m), 2.52 (6 H, s), 3.15 (2 H, ddd, J = 4.7, 4.7, and 8.7).  
δC (CDCl3): 12.4, 13.5, 14.8, 17.2, 18.9, 27.4, 29.8, 69.8, 82.9, 131.0, 132.7, 135.7, 
143.6, 152.4. 
δB (CDCl3): 0.61 (t, J = 33.4).  
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δF (CDCl3): −145.9 (q, J = 33.4), −145.8 (q, J = 33.4).  
C22H30BF2N2
+ requires 371.24701, ESI [M + H]+ found 371.2477. 
 
 
4.2.28 4,4-Difluoro-4-bora-1,3,5,7-tetramethyl-2,6-diethyl-8-(pent-5-bromide) 
3a,4a-diaza-s-indacene  
 
183 
A solution of bromo-hexanoyl chloride 182 (1.24 mL, 8.10 mmol) in dry 
dichloromethane (60 ml) was added drop-wise to a stirred solution of 3-ethyl-2-4-
dimethyl pyrrole (2.1 mL, 16.23 mmol) in dry dichloromethane (20 mL). After the 
mixture was heated under reflux for 4 h, the reaction mixture was cooled to room 
temperature followed by addition of dry trimethylamine (2.34 mL, 16.77 mmol). After 
the mixture was stirred for 30 min under reflux, boron trifluoride diethyl etherate (2.0 
mL, 16.20 mmol) was added and the reaction mixture was stirred for 4 h under reflux. 
Upon cooling to room temperature, reaction mixture was diluted with saturated 
NaHCO3 solution (20 mL) and products were extracted with dichloromethane (3×50 
mL) and the combined organic layer was washed with saturated NaHCO3 solution 
(2×20 mL). The organic layers were dried (MgSO4) and evaporated under reduced 
pressure. The residue was purified by column chromatography on silica gel. The 
appropriate fractions, which were eluted by ethyl acetate–hexane (20:80, v/v), were 
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combined and evaporated under reduced pressure to give the title compound a red solid 
(1.2 g, 2.84 mmol, 35% ) 
δH(CDCl3): 1.07 (6 H, t, J = 7.6), 1.66–1.70 (4 H, m), 1.94–1.96 (2 H, m), 2.35 (6 H, 
s), 2.42 (4 H, q, J = 7.2), 2.51 (6 H, s), 3.02 (2 H, m), 3.46 (2 H, t, J = 6.4).  
δC(CDCl3): 12.4, 13.4, 14.8, 17.2, 28.3, 28.5, 30.8, 32.2, 33.4, 130.8, 132.6, 135.5, 
144.2, 152.2.  
 
4.2.29 4,4-Difluoro-4-bora-1,3,5,7-tetramethyl-2,6-diethyl-8-(5-azidopentyl)-
3a,4a-diaza-s-indacene  
 
184 
To a solution of 4,4-difluoro-4-bora-1,3,5,7-tetramethyl-2,6-diethyl-8-(5-
bromopentyl)-3a,4a-diaza-s-indacene 183 (30 mg, 0.0663 mmol) in water (1.0 mL)–
DMF (100 μL) was added NaN3 (6.46 mg, 0.0994 mmol) and the reaction mixture was 
heated in a CEM microwave reactor at 100°C for 10 min under stirring. Upon cooling, 
the products were diluted with water (2 mL) and extracted with ethyl acetate (2×6 mL). 
The organic layers were dried (MgSO4) and evaporated under reduced pressure. The 
crude products were purified by column chromatography on silica gel. The appropriate 
fractions, which were eluted with ethyl acetate–hexanes (20:80, v/v), were combined 
and evaporated under reduced pressure to give the title compound as a red solid (22 mg, 
80%). 
Rf: 0.38 (System C):  
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δH(CDCl3): 1.07 (6 H, t, J = 7.5), 1.56–1.73 (6 H, m), 2.35 (6 H, s), 2.42 (4 H, q, J = 
7.5), 2.52 (6 H, s), 3.02 (2 H, m), 3.34 (2 H, t, J = 6.6).  
δC(CDCl3): 12.4, 13.4, 14.8, 17.2, 27.3, 28.3, 28.7, 31.3, 51.3, 130.9, 132.7, 135.3, 
144.2, 152.2.  
δB(CDCl3): 0.61 (t, J = 33.5).  
δF(CDCl3): -146.0 (q, J = 33.5), -145.9 (q, J = 33.5). 
 
4.2.30 Conjugation between β-Glc-PEG2-N3 (176) and 4,4-difluoro-4-bora-1,3,5,7-
tetramethyl-2,6-diethyl-8-(hex-5-ynyl)-3a,4a-diaza-s-indacene (181) 
 
 
185 
To a solution of β-Glc-PEG2-N3 176 (5.0 mg, 0.015 mmol) in water (100 μL) was added 
a solution of 4,4-difluoro-4-bora-1,3,5,7-tetramethyl-2,6-diethyl-8-(hex-5-ynyl)-3a,4a-
diaza-s-indacene 181 (6.0 mg, 0.016 mmol) in DMF (200 μL), a solution of cupric 
sulfate (50 μL, 13 mol%, stock solution prepared by dissolving 200 mg cupric sulfate  
pentahydrate in 20 mL of water), and a solution of sodium L-ascorbate (75 μL, 25 
mol%, stock prepared by dissolving 200 mg of sodium L-ascorbate in 20 mL of water). 
The reaction mixture was then heated in a CEM microwave at 80°C for 3 min and was 
diluted with water (2 mL) upon cooling. The products were extracted with diethyl ether 
(2×6 mL) and the aqueous solution was purified by FPLC column chromatography on 
C18 reverse phase silica gel (1×30 cm). The column was eluted with a linear gradient 
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of mixture of acetonitrile and water (40 to 80% acetonitrile over 100 min). The 
appropriate fractions were combined and lyophilized to give the title compound as a 
red sponge solid (7.5 mg, 71%). 
Rf: 0.60 (System K).  
δH(CD3OD): 1.07 (6 H, t, J = 7.6), 1.96–2.02 (2 H, m), 2.26 (6 H, s), 2.45 (6 H, s), 2.45 
(4 H, q, J = 7.6), 2.95 (2 H, t, J = 7.1), 3.08–3.12 (2 H, m), 3.18 (1 H, dd, J = 7.6 and 
8.6, H-2),  3.25–3.39 (3 H, m, overlap with CD3OD solvent residue), 3.60–3.68 (10 H, 
including CH2, a dd with J = 5.7 and 12 for H-6a, and one of the two protons in the 
PEG-CH2 attached to the glycsidic linkage), 3.78 – 3.97 (4 H, including a dd with J = 
2.1 and 12 for H-6b, and the other proton in the PEG-CH2 attached to the glycsidic 
linkage), 3.90 (2 H, t, J = 5.0, CH2), 4.25 (1 H, d, J = 7.8, H-1), 4.59 (2 H, t, J = 5.0, 
CH2), 7.92 (1 H, s, CH triazole). 
δC(CD3OD): 11.1, 12.1, 13.8, 16.5, 25.0, 27.3, 31.5, 49.9, 61.3 (C6), 68.2, 69.0, 69.9, 
70.0, 70.2 (C5), 73.7 (C2), 76.53 and 76.56 (C3 and C4), 103.0 (C1), 123.4, 130.7, 
132.5, 136.0, 144.5, 146.3, 151.8.  
δB (CD3OD): 0.54 (t, J = 33.3).  
δF (CD3OD): -146.5 to -146.2 (m) 
C34H53BF2N5O8
+ requires 708.39553, ESI [M+H]+ found 708.3932.  
 
4.2.31 Conjugation between β-GlcNAc-PEG2-N3 (177) and 4,4-difluoro-4-bora-
1,3,5,7-tetramethyl-2,6-diethyl-8-(hex-5-ynyl)-3a,4a-diaza-s-indacene (181) 
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186 
To a solution of β-GlcNAc-PEG2-N3 177 (5.0 mg, 0.013 mmol) in water (100 μL) was 
added a solution of 4,4-difluoro-4-bora-1,3,5,7-tetramethyl-2,6-diethyl-8-(hex-5-
ynyl)-3a,4a-diaza-s-indacene 181 (5.8 mg, 0.016 mmol) in DMF (200 μL), a solution 
of cupric sulfate (50 μL, 15 mol%, stock prepared by dissolving 200 mg cupric sulfate  
pentahydrate  in 20 mL of water), and a solution of sodium L-ascorbate (75 μL, 29 
mol%, stock prepared by dissolving 200 mg of sodium L-ascorbate in 20 mL of water). 
The reaction mixture was then heated in a CEM microwave at 80°C for 3 min and was 
diluted with water (2 mL) upon cooling. The products were extracted with diethyl ether 
(2×6 mL) and the aqueous solution was purified by FPLC column chromatography on 
C18 reverse phase silica gel (1×30 cm). The column was eluted with a linear gradient 
of mixture of acetonitrile and water (40 to 80% acetonitrile over 100 min). The 
appropriate fractions were combined and lyophilized to give the title compound as a 
red sponge solid (7.0 mg, 72%).  
Rf: 0.53 (System K).  
δH(CD3OD): 1.06 (6 H, t, J = 7.6), 1.95 (3 H, s), 1.96 (2 H, m), 2.25 (6 H, s), 2.45 (6 
H, s), 2.45 (4 H, q, J = 7.6), 2.94 (2 H, t, J = 7.1), 3.06–3.10 (2 H, m), 3.23 (1 H, ddd, 
J = 2.2, 5.7 and 9.5, H5), H4 overlaps with deuterated methanol solvent residue, 3.43 
(1 H, dd, J = 8.6 and 10, H3), 3.54–3.70 (9 H, m, 3×CH2, H2, H6a, and one of the 
protons of the PEG-CH2 attached to the gycosidic linkage), 3.85–3.91 (4 H, including 
a dd, J = 2.2 and 10.3 for H6b, the other proton of the PEG-CH2 attached to gycosidic 
linkage, and CH2), 4.38 (1 H, d, J = 8.2, H1), 4.58 (2 H, t, J = 5.0), 7.91 (1 H, s).  
δC(CD3OD): 11.1, 12.1, 13.8, 16.5, 21.6, 25.0, 27.3, 31.5, 49.9, 55.9 (C2), 61.4 (C6), 
68.6, 69.0, 70.0, 70.1, 70.2, 70.7 (C4), 74.8 (C3), 76.6 (C5), 101.3 (C1), 123.3, 130.7, 
132.6, 136.0, 144.5, 146.3, 151.8, 172.2.  
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δB(CD3OD): 0.53 (t, J = 33.3).  
δF(CD3OD): -146.5 to -146.2 (m). 
C36H56BF2N6O8
+ requires 749.42207, ESI [M+H]+ found 749.4232.  
 
4.2.32 Conjugation between β-Lac-PEG2-N3 (178) and 4,4-difluoro-4-bora-1,3,5,7 
tetramethyl-2,6-diethyl-8-(hex-5-ynyl)-3a,4a-diaza-s-indacene (181) 
 
 
 
187 
To a solution of β-Lac-PEG2-N3 178 (5.0 mg, 0.010 mmol) in water (100 μL) was added 
a solution of 4,4-difluoro-4-bora-1,3,5,7-tetramethyl-2,6-diethyl-8-(hex-5-ynyl)-3a,4a-
diaza-s-indacene 181 (4.5 mg, 0.011 mmol) in DMF (200 μL), a solution of cupric 
sulfate (50 μL, 20 mol%, stock prepared by dissolving 200 mg cupric sulfate 
pentahydrate in 20 mL of water), and a solution of sodium L-ascorbate (75 μL, 37 
mol%, stock prepared by dissolving 200 mg of sodium L-ascorbate in 20 mL of water). 
The reaction mixture was then heated in a CEM microwave at 80°C for 3 min and was 
diluted with water (2 mL) upon cooling. The products were extracted with diethyl ether 
(2×6 mL) and the aqueous solution was purified by FPLC column chromatography on 
C18 reverse phase silica gel (1×30 cm). The column was eluted with a linear gradient 
of mixture of acetonitrile and water (40 to 80% acetonitrile over 100 min). The 
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appropriate fractions were combined and lyophilized to give the title compound as a 
red sponge solid (7.4 mg, 85%). 
Rf: 0.36 (System K).  
δH (CD3OD): 1.07 (6 H, t, J = 7.4), 1.99 (2 H, ddd, J = 7.2, 11.5, and 12.0), 2.26 (6 H, 
s), 2.45 (6 H, s), 2.46 (4 H, q, J = 7.5), 2.96 (2 H, t, J = 7.0), 3.08–3.13 (2 H, m, CH2), 
3.24 (1 H, t, J = 8.5, H2Glc), 3.32–3.63 (multiple unresolved signals, including 
deuterated methanol solvent residue signals), 3.69 – 3.85 (4 H, m, H6Glc and H6Gal), 
3.88 – 3.95 (m, including 1×CH2 and one of the two protons of the PEG-CH2 attached 
to the glycosidic linkage), 4.26 (1 H, d, J = 7.8, H1Glc), 4.35 (1 H, d, J = 7.5 H1Gal), 
4.59 (2 H, t, J = 4.9, CH2), 7.93 (1 H, s, triazole).  
δC (CD3OD): 11.1, 12.1, 13.8, 16.5, 25.0, 27.3, 31.5, 49.9, 60.5, 61.6, 68.3, 68.9, 69.0, 
70.0, 70.1, 71.1, 73.3, 73.4, 74.9, 75.0, 75.7, 79.2, 123.4, 130.7, 132.6, 136.0, 144.5, 
146.2, 151.8. 
δB (CD3OD): 0.53 (t, J = 33.2).  
δF (CD3OD): -146.5 to -146.2 (m). 
C40H63BF2N5O13
+ requires 870.44835, ESI [M+H]+ found 870.4497. 
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4.2.33 Conjugation between β-GlcNAc-PEG3-propyne (179) and 4,4-difluoro-4-
bora-1,3,5,7-tetramethyl-2,6-diethyl-8-(5-azidopentyl)-3a,4a-diaza-s-indacene 
(184) 
 
 
188 
To a solution of β-GlcNAc-PEG3-propyne 179 (5.0 mg, 0.013 mmol) in water (100 μL) 
was added a solution of 4,4-difluoro-4-bora-1,3,5,7-tetramethyl-2,6-diethyl-8-(hex-5-
ynyl)-3a,4a-diaza-s-indacene 184 (6.4 mg, 0.015 mmol) in DMF (200 μL), a solution 
of cupric sulfate (50 μL, 15 mol%, stock prepared by dissolving 200 mg cupric sulfate  
pentahydrate in 20 mL of water), and a solution of sodium L-ascorbate (75 μL, 30 
mol%, stock prepared by dissolving 200 mg of sodium L-ascorbate in 20 mL of water). 
The reaction mixture was then heated in a CEM microwave at 80°C for 3 min and was 
diluted with water (2 mL) upon cooling. The products were extracted with diethyl ether 
(2×6 mL) and the aqueous solution was purified by FPLC column chromatography on 
C18 reverse phase silica gel (1×30 cm). The column was eluted with a linear gradient 
of mixture of acetonitrile and water (40 to 80% acetonitrile over 100 min). The 
appropriate fractions were combined and lyophilized to give the title compound as a 
red sponge solid (7.7 mg, 73%). 
Rf: 0.56 (System K).  
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δH (CD3OD): 1.07 (6 H, t, J = 7.6), 1.49–1.57 (2 H, m, CH2), 1.63–1.71 (2 H, m, CH2), 
1.96 (3 H, s), 1.98–2.07 (2 H, m, CH2), 2.35 (6 H, s), 2.45 (6 H, s), 2.46 (4 H, q, J = 
7.6), 2.99–3.03 (2 H, m, CH2), 3.24–3.35 (2 H, m, H4 and H5, overlap with deuterated 
methanol solvent residue), 3.45 (1 H, dd, J = 8.3 and 10.0, H3), 3.60 – 3.74 (13 H, m, 
H2, H6a, one of the protons of the PEG-CH2 attached to glycosidic linkage, and five 
other CH2 of PEG), 3.88 (1 H, dd, J = 2.1 and 11.7, H6b), 3.92 (1 H, dt, J = 4.3 and 7.7, 
the other proton of the PEG-CH2 attached to glycosidic linkage), 4.45 (2 H, t, J = 7.0, 
CH2), 4.49 (1 H, d, J = 8.4, H1), 4.66 (2 H, s, CH2), 8.01 (1 H, s, triazole proton).  
δC (CD3OD): 11.1, 12.2, 13.8, 16.5, 21.6, 26.4, 27.8, 29.5, 30.8, 49.7, 55.9 (C1), 61.4 
(C6), 63.5, 68.4, 69.3, 70.1, 70.2, 70.3, 70.7 (C4), 74.9 (C3), 76.6 (C5), 101.5 (C1), 
123.7, 130.7, 132.5, 136.0, 144.6, 144.8, 151.7, 172.4. 
δB (CD3OD): 0.54 (t, J = 33.0).  
δF (CD3OD): -146.6 to -146.3 (m). 
C39H62BF2N6O9
+ requires 807.46394, ESI [M+H]+ found 807.4652.  
 
4.2.34 Liposome preparation  
Conjugate 185 (2.0 mg, 2.8 μmol) was dissolved in chloroform (1 mL) and evaporated 
under reduced pressure. The residue was dried further in vacuo for 1 h. To the dried 
material, HPLC grade water (3 mL) pre-heated at 60°C, followed by 10 glass beads (2 
mm diameter), were added, and the mixture was gently swirled for 2 min. After 
incubation at 70°C for 1 h, the mixture was slowly cooled down to room temperature 
over 70 min to give liposomes that were analyzed by bright field and fluorescent 
confocal microscopy. 
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